

1 **Histopathological growth patterns of liver metastasis: updated consensus guidelines for**
2 **pattern scoring, perspectives, and recent mechanistic insights.**

3
4 Emily Latacz^{1,*}, Diederik Höppener^{2,*}, Ali Bohlok^{3,*}, Sophia Leduc⁴, Sébastien Tabariès⁵,
5 Carlos Fernández Moro^{6,7}, Claire Lugassy⁸, Hanna Nyström^{9,10}, Béla Bozóky⁷, Giuseppe
6 Floris^{11,12}, Natalie Geyer¹³, Pnina Brodt¹⁴, Laura Llado¹⁵, Laura Van Mileghem¹, Maxim De
7 Schepper⁴, Ali W.Majeed¹⁶, Anthoula Lazaris¹⁷, Piet Dirix¹, Qianni Zhang¹⁸, Stéphanie K.
8 Petrillo¹⁷, Sophie Vankerckhove³, Ines Joye¹, Yannick Meyer², Alexander Gregorieff^{17,19,20},
9 Nuria Ruiz Roig^{21,22,23}, Fernando Vidal-Vanaclocha²⁴, Larsimont Denis²⁵, Rui Caetano
10 Oliveira^{26,27,28}, Peter Metrakos¹⁷, Dirk J. Grünhagen², Iris D. Nagtegaal²⁹, David G. Mollevi^{22,30},
11 William R Jarnagin³¹, Michael I D'Angelica³¹, Andrew R. Reynolds³², Michail Doukas³³,
12 Christine Desmedt⁴, Luc Dirix¹, Vincent Donckier^{3,*}, Peter M. Siegel^{5,34,*}, Raymond
13 Barnhill^{8,35,*}, Marco Gerling^{13,36,*}, Cornelis Verhoef^{2,*}, Peter B. Vermeulen^{1,*},✉

14
15 *These authors contributed equally

16 ✉ email: peter.vermeulen@gza.be

17
18 ¹Translational Cancer Research Unit (GZA Hospitals, Iridium Network and University of
19 Antwerp), Antwerp, Belgium.

20 ²Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

21 ³Department of surgical oncology, Institut Jules Bordet, Brussels, Belgium.

22 ⁴Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven,
23 Leuven, Belgium.

24 ⁵Department of Medicine, Rosalind and Morris Goodman Cancer Research Institute, McGill
25 University, Montreal, Quebec, Canada.

26 ⁶Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Huddinge,
27 Sweden.

28 ⁷Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital,
29 Huddinge, Sweden.

30 ⁸Department of Translational Research, Institut Curie, Paris, France.

31 ⁹Department of Surgical and Perioperative Sciences, Surgery, Umeå University, Umeå,

32 ¹⁰Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Huddinge, Sweden.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 33 ¹⁰Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden.
- 34 ¹¹Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research
35 and University Hospitals Leuven, KU Leuven, Leuven, Belgium.
- 36 ¹²Department of Pathology, University Hospitals Leuven, Campus Gasthuisberg, Leuven,
37 Belgium.
- 38 ¹³Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.
- 39 ¹⁴Department of Surgery, Oncology and Medicine, McGill University and the Research
40 Institute, McGill University Health Center, Montreal, Quebec, Canada.
- 41 ¹⁵HBP and Liver Transplantation Unit, Department of Surgery, Hospital Universitari de
42 Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
- 43 ¹⁶Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.
- 44 ¹⁷Cancer Research Program, McGill University Health Centre Research Institute, Montreal,
45 Quebec, Canada.
- 46 ¹⁸School of Electronic Engineering and Computer Science, Queen Mary University of London,
47 London, UK.
- 48 ¹⁹Department of Pathology, McGill University, Montreal, Quebec, Canada.
- 49 ²⁰ Regenerative Medicine Network, McGill University, Montreal, Quebec, Canada.
- 50 ²¹Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat,
51 Barcelona, Catalonia, Spain.
- 52 ²²Tumoral and Stromal Chemoresistance Group, Oncobell Program, IDIBELL, L'Hospitalet de
53 Llobregat, Barcelona, Catalonia, Spain.
- 54 ²³Human Anatomy and Embryology Unit, Department of Pathology and Experimental
55 Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona,
56 Catalonia, Spain.
- 57 ²⁴GWU-Cancer Center, Department of Biochemistry and Molecular Medicine, School of
58 Medicine & Health Sciences, The George Washington University, Washington DC, USA.
- 59 ²⁵Department of Pathology, Institut Jules Bordet, Brussels, Belgium.
- 60 ²⁶Pathology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
- 61 ²⁷Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal.
- 62 ²⁸Coimbra Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics
63 and Oncobiology (CIMAGO), Institute of Biophysics, Faculty of Medicine, University of
64 Coimbra, Coimbra, Portugal.

65 ²⁹Department of Pathology, Radboud University Medical Center, Nijmegen, Netherlands.

66 ³⁰Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia,
67 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.

68 ³¹Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

69 ³²Oncology R&D, AstraZeneca, Cambridge, UK.

70 ³³Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands

71 ³⁴Departments of Medicine, Biochemistry, Anatomy & Cell Biology, McGill University,
72 Montreal, Quebec, Canada.

73 ³⁵Université de Paris l'UFR de Médecine, Paris, France.

74 ³⁶Theme Cancer, Karolinska University Hospital, Solna, Sweden.

75

76 **Funding**

77 The work by CD, PV, GF, VD, LD, and DL on breast cancer liver metastasis is supported by the
78 Foundation against Cancer (Stichting tegen Kanker, Grant C/2020/1441). PV and LD are
79 supported by the Koning Boudewijnstichting. GF is a recipient of a post-doctoral mandate
80 sponsored by the KOOR from the University Hospitals Leuven. PS is a William Dawson
81 Scholar of McGill University and acknowledges funding from the Canadian Institutes of
82 Health Research (CIHR: MOP-136907; PJT-175088). HN is supported by the Swedish Research
83 Council, Wallenberg Foundations/Knut and Alice Wallenberg Foundation, Region
84 Västerbotten, the Swedish Cancer Society, the Cancer Research Foundation in Northern
85 Sweden and Umeå University. MG is supported by The Swedish Research Foundation (2018-
86 02023) and The Swedish Association for Medical Research. QZ is supported by Engineering
87 and Physical Sciences Research Council (project EP/N034708/1). DGM is supported by the
88 Fondo de Investigaciones Sanitarias of the Spanish Government, Fondo Europeo de
89 Desarrollo Regional (FEDER) "Una manera de hacer Europa" / "A way of shaping Europe"
90 (grant PI18/1140) and by AGAUR Department of Health of the Generalitat de Catalunya
91 (grant SGR771). WRJ is supported by grant U01 CA238444-02 from the National Cancer
92 Institute.

93

94 **Acknowledgement**

95 The current guidelines are the result of numerous discussions at the annual meetings of the
96 international Liver Metastasis Research Network.

97

98 **Conflict of interest**

99 All authors declare that there are no competing financial interests or other conflicts of
100 interest.

101

102 **Abstract (word count: 191)**

103 The first consensus guidelines for scoring the histopathological growth patterns (HGPs) of liver
104 metastases were established in 2017. Since then, numerous studies have applied these
105 guidelines, have further substantiated the potential clinical value of the HGPs in patients with
106 liver metastases from various tumour types and are starting to shed light on the biology of the
107 distinct HGPs. In the present guidelines, we give an overview of these studies, discuss novel
108 strategies for predicting the HGPs of liver metastases, such as deep learning algorithms for
109 whole slide histopathology images and medical imaging, and highlight liver metastasis animal
110 models that exhibit features of the different HGPs. Based on a pooled analysis of large cohorts
111 of patients with liver-metastatic colorectal cancer, we propose a new cut-off to categorize
112 patients according to the HGPs. An up-to-date standard method for HGP assessment within
113 liver metastases is also presented with the aim of incorporating HGPs into the decision-making
114 processes surrounding the treatment of patients with liver metastatic cancer. Finally, we
115 propose hypotheses on the cellular and molecular mechanisms that drive the biology of the
116 different HGPs, opening some exciting pre-clinical and clinical research perspectives.

117

118 Introduction

119 The histopathological growth patterns (HGP) of liver metastases are a morphological
120 reflection of the distinct ways in which cancer cells interact with the surrounding liver. These
121 HGPs can be identified by light microscopy on tissue sections that include the metastasis-liver
122 interface. In 2017, the first set of guidelines for scoring the growth patterns was published¹.
123 Since that time, numerous additional studies have utilized these consensus guidelines to score
124 the HGPs of liver metastases. These studies, listed in Table 1, have further substantiated the
125 clinical value of HGPs in hepatic metastases from colorectal cancer and extended this concept
126 to other tumour types, such as breast carcinoma, melanoma, and pancreatic cancer.
127 Moreover, these publications have significantly increased our understanding of HGP biology
128 by describing the molecular and cellular differences between growth patterns by, for example,
129 looking at growth pattern-specific immune responses²⁻⁶. In addition, attempts have been
130 made to develop technologies for predicting HGPs using medical imaging and machine-
131 learning algorithms⁷⁻¹⁰. Novel animal models for liver metastasis exhibiting features of the
132 different HGPs are a particularly valuable development¹¹⁻¹⁷. These models will allow us to: 1)
133 perform functional validation of HGP-specific signalling pathways described in the clinical
134 samples of liver metastases, 2) identify non-invasive surrogate markers for the different HGPs
135 and 3) test the efficacy of new therapeutic strategies based on the HGPs.

136 Clinical and experimental studies have provided ample new information that warrants an
137 updated, second version of the international guidelines for scoring the HGPs in the context of
138 liver metastasis. The main goal of the guidelines is to incorporate these histological features
139 into the clinical decision-making processes surrounding the treatment of patients with liver
140 metastatic cancer. We therefore provide a detailed histopathological description of the
141 growth patterns of liver metastases and propose an updated standard method for HGP
142 assessment within liver metastases, including immunohistochemical staining as an aid to
143 scoring HGPs. One of the important features of the new guidelines is a modified and clinically
144 applicable cut-off for considering a colorectal cancer (CRC) liver metastasis (CRLM) as
145 desmoplastic or non-desmoplastic. This change in cut-off is supported by retrospective studies
146 with large cohorts of patients with liver metastatic CRC^{18,19}. In the new guidelines, we present
147 a pooled analysis of previously published cohorts to demonstrate the improved prognostic
148 value of this new cut-off recommendation. In addition, we propose hypotheses that could
149 explain the transition from one HGP to another, based on comprehensive

150 immunohistochemical analyses of both the tumour-liver interface and the centre of the
151 metastases. We also speculate on molecular mechanisms that may underlie the biological
152 differences of the growth patterns. Finally, we discuss exciting new research perspectives for
153 the HGPs, including digital image processing techniques and deep learning methods for
154 automated HGP scoring using digitized haematoxylin-and-eosin-stained (H&E-stained) tissue
155 sections²⁰⁻²².

156

157

158 **Methods**

159 Literature search

160 We performed a literature search for studies published since January 2015 that focused on
161 the HGPs of liver metastases using the PubMed^R resource of the U.S. National Library of
162 Medicine. The search terms were designed to find studies on the evaluation of the interface
163 between liver metastases and the surrounding liver tissue, independent of the primary
164 tumour type and the host species. Additional studies were found by manual cross-referencing.
165 Ultimately, manuscripts were selected by three reviewers (EL, DJH and PV). Only manuscripts
166 that were not already presented in Table 1 of the first consensus guidelines publication¹ are
167 discussed in the current overview table (Table 1).

168

169 Evaluation of the HGP cut-off algorithms

170 To compare the prognostic value of different HGP cut-off algorithms, survival analyses were
171 performed. The HGP and survival data used for these analyses have been previously published
172 as separate cohorts and were pooled for the current analysis^{1,18,23-25}. All available H&E-stained
173 sections of all resected liver metastases for every patient included in this assessment were
174 analysed according to the 2017 consensus guidelines¹. The final HGP score per patient is the
175 average of all metastases, independent of the size of the metastases or number of analysed
176 tissue sections per metastasis. Data on overall and disease-free survival (OS, DFS, defined as
177 the time between first liver metastasis resection and death or cancer recurrence, respectively)
178 and HGP were available for 1931 patients: 903 patients underwent surgical resection (1998 -
179 2019) in the Erasmus MC Cancer Institute (Rotterdam, the Netherlands), 716 patients in the
180 Memorial Sloan Kettering Cancer Center (New York, NY, USA), and 312 patients in the
181 Radboud University Medical Centre (Nijmegen, the Netherlands). All patients treated with
182 curative intent, who did not receive hepatic arterial infusion pump chemotherapy, and for
183 whom H&E-stained sections were available, were included. Approval by the institutional
184 ethical review boards was obtained in each individual centre separately.

185

186 Immunohistochemistry

187 For immunohistochemistry with antibodies (clone; manufacturer's code) directed at CK7
188 (RN7; NCL-L-CK7-560), CK18 (DC-10; NCL-CK18), CK19 (b170; NCL-CK19), CK20 (PW31; NCL-L-
189 CK20-561), Caldesmon (H-CD; Dako-M3557), CD34 (QBEnd/10; Dako-M7165), CD146

190 (UMAB154; Origene-UM800051), NGFR (polyclonal; Atlas-HPA004765) and alpha-SMA (1a4;
191 DAKO-M0851), formalin-fixed paraffin-embedded (FFPE) tissue representing the respective
192 areas were cut to 4 µm thickness. All immunohistochemical stains were done on a Leica
193 (Germany) BOND-MAX automated stainer as part of clinical routine at Karolinska University
194 Hospital, Huddinge, Sweden. Pretreatment was done using Bond Epitope Retrieval Solution 2
195 EDTA (Leica) for 20 minutes. Immunohistochemistry for antibodies directed at melan-A (A103;
196 Dako-M7196) was done on a Leica BOND-RX automated stainer at Institut Curie, Paris, France.
197 Pretreatment was done using Bond Epitope Retrieval Solution 2 EDTA (Leica) for 20 minutes.

198

199 Statistics

200 For the comparison of different cut-off algorithms, OS and DFS were estimated using the
201 Kaplan-Meier method and reported as 5-year (%), 10-year (%) and median (months) survival
202 including a corresponding 95% confidence interval (CI). Adjusted hazard ratios (HR) for OS and
203 DFS are based on multivariable Cox proportional hazards regression models. All statistical
204 analyses were performed with the R Project for Statistical Computing (version 4.0.2;
205 <https://www.r-project.org/>).

206

207 **Results**

208 **Guidelines**

209 **Histopathological description of the growth patterns of liver metastases**

210 Liver metastases can interact differently with the liver parenchyma as they colonise the liver,
211 which is manifest histologically as one of several distinct growth patterns. These patterns can
212 generally be identified by light microscopy in H&E-stained sections of FFPE tissue at the
213 interface between the cancer cells and the liver parenchyma²⁶⁻³⁰. The key histopathological
214 characteristics of the HGPs have been described in Table 2 of the first international consensus
215 guidelines¹ and remain valid in that form. An updated overview of the histology of the
216 different HGPs is presented in Table 2 and in Figures 1A-K of the current scoring guidelines.

217 The desmoplastic and the replacement HGPs are the most common patterns, based on recent
218 studies that have used the 2017 consensus guidelines (Table 1). For example, either the
219 desmoplastic or the replacement HGP was evident in 97.5% of the tumour-liver interface of
220 all CRC liver metastases of 732 patients¹⁸, almost equally distributed between both HGPs. In
221 the desmoplastic HGP, the cancer cells are separated from the surrounding liver parenchyma
222 by a fibrotic rim. Often a dense infiltrate of immune cells is present at the transition between
223 the liver parenchyma and the fibrous rim. Desmoplastic liver metastases frequently show
224 glandular differentiation (when derived from an adenocarcinoma) and are vascularized by a
225 process of angiogenesis³¹ (Figures 1A-C).

226 In replacement-type liver metastases, cancer cells are in contact with the hepatocytes, they
227 replace the hepatocytes, and, in the process, they co-opt the sinusoidal blood vessels of the
228 liver. As a result, the tissue architecture of the metastases with this HGP mimics the tissue
229 architecture of the liver, such that the metastatic cancer cells arrangement recapitulates
230 'hepatic cell plates' in between co-opted hepatic sinusoidal blood vessels. Typically, and based
231 on observations done in carcinoma liver metastases, only a few immune cells are present at
232 the tumour-liver interface and in the tumour centre³², although this is not a scoring criterion.

233 Adenocarcinoma metastases with a replacement growth pattern do not usually show
234 glandular differentiation at the tumour-liver interface (Figures 1D-F). Angiotropic
235 extravascular migration has been observed in replacement-type liver metastases of
236 melanoma³³ (see section dedicated to angiotropic extravascular migration): single or small
237 clusters of melanoma cells may extend along sinusoidal channels into the surrounding liver
238 parenchyma with distances of several millimeters.

239 The pushing growth pattern is an uncommon pattern. For example, the pushing HGP was
240 present in only 2.5% of the tumour-liver interface of all CRC liver metastases of 732 patients¹⁸.
241 This growth pattern is characterized by cancer cells that appear to push away the liver
242 parenchyma without an intervening fibrous rim. Cancer cells do not invade the hepatocyte
243 plates, they do not replace the hepatocytes, and they do not co-opt the sinusoidal blood
244 vessels. The surrounding liver is composed of hepatocytes that are arranged parallel to the
245 tumour-liver interface and appear slender because they are atrophic or compressed by the
246 growing metastases (Figures 1G and 1H).

247 Liver metastases with a sinusoidal HGP are characterized by cancer cells that fill the sinusoidal
248 vascular spaces (Figure 1I). The sinusoidal HGP appears limited to patients with aggressive
249 disease and is more frequently encountered in autopsy specimens, which could imply that it
250 is a feature of end-stage disease^{7,34-37}. Liver metastases can also spread along the portal
251 tracts. Cancer cells can invade the fibrous stroma of these tracts, fill the lumen of portal vein
252 branches or the lymphatic vessels, or grow along nerves (neurotropism) and blood vessels
253 (angiotropism). In addition, cancer cells can proliferate inside biliary ducts of the portal tracts
254 by replacing the normal epithelial lining of these ducts (Figures 1J and 1K).

255 Tumour type-dependent differences in the growth patterns have been described. For
256 example, when comparing the replacement HGP in breast cancer metastases and CRLM, the
257 histological characteristics of replacement growth were often present from the tumour-liver
258 interface and up to the centre of the metastases in the breast cancer cases, while they were
259 limited to the interface in all CRLM³⁸. Also, the presence of single cancer cells in the liver
260 parenchyma at a distance from the tumour-liver interface in replacement-type liver
261 metastases (so called angiotropic extravascular migration) appears to be more obvious in
262 melanoma liver metastases than in liver metastases of CRC or other carcinomas (unpublished
263 observations).

264

265 **Update of the cut-off value to categorize patients with colorectal cancer according to the** 266 **histopathological growth pattern of the liver metastases**

267 Given that a single liver metastasis can be composed of regions with different growth patterns,
268 this histological parameter is assessed by estimating the relative fraction of the total length of
269 the interface for each growth pattern present in the metastasis. In cases of multiple sections
270 per metastasis or multiple liver metastases per patient, the mean percentage across sections

271 and lesions, respectively, is calculated¹. In the previous version of the scoring guidelines, a
272 50% cut-off was proposed to categorize patients, based on its prognostic value. This approach
273 generated four distinct HGP classes: ‘predominant desmoplastic’, ‘predominant replacement’,
274 ‘predominant pushing’ and a ‘mixed’ class in the absence of a predominant HGP. Multiple
275 studies have demonstrated a favourable outcome in patients with CRC liver metastases with
276 a predominant desmoplastic HGP (Table 1).

277 However, the results of a study by Galjart and colleagues from the Erasmus Medical Centre in
278 Rotterdam¹⁸ provide a strong rationale for revising the cut-off value used to clinically
279 categorize patients with CRC liver metastases according to the HGP. The study compared
280 different cut-offs based on a large dataset of patients with CRLM. The results suggest that the
281 prognosis of patients with resected CRC liver metastases is primarily determined by the
282 presence of a replacement and/or a pushing growth pattern as opposed to a pure
283 desmoplastic growth pattern (corresponding to 100% of the assessed tumour-liver interface).
284 Favourable survival rates were demonstrated only for patients with liver metastases with
285 complete desmoplastic growth, a condition present in 24% of all patients included in the study
286 by Galjart et al (2019)¹⁸. Remarkably, non-desmoplastic growth - of any fraction - reduced the
287 5-year OS rate from 78% to 37% in the cohort of patients who did not receive pre-surgery
288 systemic treatment (adjusted HR 0.39; 95% CI: 0.23-0.67) and from 53% to 40% in the cohort
289 of patients who did receive pre-surgery systemic treatment (adjusted HR 0.92; 95% CI: 0.64-
290 1.30). This difference in outcome was recently confirmed in a large multicentre external
291 validation study¹⁹.

292 We now present a comprehensive clinical evaluation of a large international multicentre
293 cohort of 1931 patients with CRC in which we assessed the impact on outcome using the
294 recent ‘Rotterdam cut-off’^{18,19} compared to the ‘predominant HGP cut-off’ described in the
295 original international consensus guidelines¹. The clinicopathological baseline and treatment
296 characteristics are summarized in Table 3. The median follow-up for survivors was 67 months
297 (interquartile range: 34 – 112 months). When applying the Rotterdam cut-off, 1516 (79%)
298 patients had non-desmoplastic liver metastases and 21% had pure desmoplastic liver
299 metastases. Of the 1516 patients with a non-desmoplastic HGP, 201 (10%), 549 (28%), 305
300 (16%), and 461 (24%) patients had liver metastases with a 100%, 67.1-99%, 33.1-67%, and 0.1-
301 33% non-desmoplastic HGP, respectively (Table 4). When patients were classified according
302 to the predominant HGP cut-off, 839 (43%) patients had liver metastases with a predominant

303 replacement HGP, 19 (1%) with a predominant pushing HGP, 1031 (53%) with a predominant
304 desmoplastic HGP, and 42 (2%) with a mixed HGP (Table 4). The following findings support the
305 ‘Rotterdam cut-off’:

- 306 1. Patients with resected CRC liver metastases that possess an exclusively desmoplastic
307 growth pattern have a clear survival advantage over all other patients. Median OS
308 (months (95% CI)) for desmoplastic versus non-desmoplastic patient cohorts is 88 (77-
309 112) versus 53 (49-58) months, respectively. Median DFS for desmoplastic versus non-
310 desmoplastic patient cohorts is 24 (20-33) versus 11 (11-12) months, respectively
311 (Figures 2A and 2B, Table 4). The adjusted HRs for OS and DFS (95% CI) are 0.64 (0.52-
312 0.78) and 0.61 (0.52-0.71), respectively (Table 4).
- 313 2. There is no difference in survival among patients belonging to the discrete non-
314 desmoplastic classes (Figures 2C and 2D, Table 4). This probably explains why the
315 survival advantage of the favourable patient cohort over the unfavourable patient
316 cohort is less pronounced when the predominant HGP cut-off algorithm is used
317 (Figures 2E and 2F, Table 4). For example, the adjusted HR for OS is 0.64 (95% CI: 0.52-
318 0.78) versus 0.76 (95% CI: 0.65-0.88) respectively, when comparing the Rotterdam and
319 the ‘predominant HGP’ cut-offs (Table 4). A similar difference of 0.61 (95% CI: 0.52-
320 0.71) versus 0.82 (95% CI: 0.73-0.93) can be observed for DFS (Table 4).
- 321 3. The learnability and accuracy of HGP-scoring according to the new cut-off have been
322 shown to be high³⁹. Moreover, this algorithm represents a simplified method of HGP
323 scoring when considering prognostic impact. Indeed, when a non-desmoplastic
324 component (replacement or pushing) is detected while analysing a series of H&E-
325 stained sections from a patient, the result is clear, and no further scoring is required.
326 However, for scientific research purposes, and to further validate the new cut-off
327 approach, care should be taken not to compromise the acquisition of more detailed
328 quantitative data and assessing the HGPs in all the available H&E-stained sections of
329 all the resected liver metastases is still preferred.

330 The international group of authors of this second consensus guidelines for scoring HGPs of
331 hepatic metastases therefore proposes to test this algorithm in prognostic studies with other
332 primary tumour types as well. In studies that aim at deciphering the molecular underpinnings
333 of the different growth patterns, a cut-off agnostic approach should probably be adopted, to
334 not obscure lessons to be learned from inter-tumour heterogeneity of the HGPs.

335

336 **Categorization of the histopathological growth patterns of non-CRC liver metastases**

337 Distinct HGPs have been identified in liver metastases from a broad range of primary solid
338 tumours, mostly carcinomas. The replacement (also referred to sometimes as ‘replacing’,
339 ‘trabecular’ or ‘infiltrative’) growth pattern, the desmoplastic growth pattern (also sometimes
340 called ‘encapsulated’) and the pushing growth pattern (also sometimes called ‘expansive’)
341 have been described in liver metastases from primary lung, pancreatic, stomach,
342 gallbladder/bile duct and breast carcinoma^{5,38,40-42}. The study of HGPs in liver metastases from
343 these tumour types is relevant given that, for example, about 11% of patients with lung
344 carcinomas, 36% of patients with pancreatic carcinoma and 14% of patients with stomach
345 cancer have liver metastases at diagnosis⁴³. The sinusoidal growth pattern has been
346 encountered in autopsy specimens of patients with non-small cell lung cancer (NSCLC) and
347 breast cancer^{7,34-37}. In addition to carcinomas, the desmoplastic, pushing, replacement and
348 sinusoidal growth patterns have also been identified in hepatic metastases of both skin and
349 uveal melanoma⁴⁴⁻⁴⁶. Additional types of HGP have also been described in uveal melanoma,
350 however without evaluation of the interface between liver metastases and the surrounding
351 liver tissue^{46,47}. In these studies, the different results reported may be ascribed to the sources
352 of material studied, almost entirely derived from autopsies, and of partial biopsy samplings.
353 The HGPs have recently also been identified in sarcoma-derived hepatic metastases, in a study
354 describing the HGPs in a cohort of patients with non-colorectal, non-neuroendocrine liver
355 metastases⁴⁸.

356 Although the prognostic/predictive role of the HGPs has been studied mainly in patients with
357 CRC^{1,18,19,49}, there are recent reports on the impact of the HGPs on outcome in patients with
358 liver metastatic melanoma, breast carcinoma and pancreatic cancer^{5,42,44,45}. In a study of 42
359 patients with skin melanoma, the presence of any replacement HGP (1% of the tumour-liver
360 interface or more), present in 20 patients (48%), significantly predicted worse overall survival
361 while the 100% desmoplastic HGP correlated with improved OS, an effect that continued to
362 be significant upon multivariate analysis (HR = 3.79, p = 0.01)⁴⁵. In a study of 41 patients with
363 liver metastatic uveal melanoma, the dominant HGP (>50% of tumour-liver interface) was
364 used to categorize patients⁴⁴. A dominant replacement HGP, present in 30 patients (73%),
365 predicted diminished OS with a HR in multivariate analysis of 6.51 (p = 0.008). An updated
366 analysis with extension of the patient cohort and categorisation according to the 100%

367 desmoplastic HGP cut-off has recently been completed (Barnhill et al, manuscript in
368 preparation).

369 The HGPs of breast cancer liver metastases have only been sporadically studied and have been
370 mainly described in autopsy specimens^{34,35,38,41}. In this context, and when compared with CRC
371 liver metastases, the replacement HGP and even the sinusoidal HGP are more frequently
372 encountered in breast cancer liver metastases. Surgical removal of breast cancer hepatic
373 metastases is still rarely practiced. However, there is a subpopulation of patients with liver
374 metastatic breast carcinoma for whom a favourable course after resection has been
375 documented, contradicting the common idea that breast cancer is always a systemic disease⁵⁰
376 and a rationale behind ongoing clinical trials, for example BreCLIM-2 (ClinicalTrials.gov
377 Identifier: NCT04079049). With this in mind, Bohlok et al (2020)⁴² have scored the HGPs in 36
378 patients who underwent surgical resection for breast cancer liver metastases. Given that only
379 one patient presented with liver metastases with a pure desmoplastic HGP while 16 patients
380 had liver metastases with a pure replacement HGP, a pragmatic approach was adopted to
381 categorize patients as having liver metastases with '100% replacement' versus 'any
382 desmoplastic' HGP. The study confirmed the association of replacement HGP liver metastases
383 with poor outcome as observed with other tumour types. Indeed, all patients with a pure
384 replacement HGP relapsed within 2 years after surgery. In addition, even in this small cohort
385 of patients, improved OS was observed for patients with 'any desmoplastic' HGP liver
386 metastases as compared to the other patients upon multivariate analysis (HR = 0.20, p =
387 0.023)⁴². A large international study has recently been undertaken by several authors of the
388 guidelines to further address the impact of the HGPs on outcome in patients with liver
389 metastatic breast cancer.

390 More than one-third of patients with neuroendocrine tumours (NETs) present with distant
391 disease, with the liver being the most common metastatic site. Although newer therapeutic
392 options are becoming available, resection of NET liver metastases is still often performed⁵¹.
393 Given the broad spectrum of NETs, from well-differentiated NETs to poorly differentiated
394 neuroendocrine carcinomas, it would be interesting to study the HGPs of NET liver
395 metastases. To the best of our knowledge, this has not been done yet.

396 In conclusion, the distinct HGPs can be identified independently of the primary solid tumour
397 type and the desmoplastic HGP is invariably associated with better outcome than the
398 replacement HGP, after surgical removal of liver metastases. This is consistent with the idea

399 that common, tumour type-independent and liver-specific biological programs are activated
400 in liver-metastatic cancer cells and shape growth pattern emergence in the liver⁵².

401

402 **Clinical significance of the pushing growth pattern**

403 The prognostic/predictive value of the pushing HGP is still unclear. Before the first
404 international guidelines were published, there were no unequivocal instructions for
405 distinguishing the pushing HGP from the replacement HGP where tumour cells appear to push
406 away the liver parenchyma (so called pushing-type or type-2 replacement HGP)¹. As a result,
407 the proportion of metastases with a pushing HGP has been overestimated in studies carried
408 out prior to the publication of the first consensus guidelines⁴⁹. For example, Nielsen et al.
409 (2014)⁵³ and Eefsen et al. (2015)⁵⁴ reported that 45% of the patients with resected CRC liver
410 metastases presented with a dominant pushing HGP. By applying the consensus guidelines of
411 2017, the proportion of metastases with a pushing HGP was found to be reproducibly smaller
412 across more recent studies. In the study by Galjart et al. of 2019¹⁸, for example, less than 1%
413 of patients presented with a dominant pushing HGP in their CRC liver metastases. Determining
414 the clinical value of the pushing HGP will therefore only be possible in large multi-centre
415 studies.

416

417 **The histopathological growth patterns and treatment response**

418 Several observations suggest that systemic treatment can alter the HGP of liver metastases.
419 In the study by Frentzas et al. (2016)⁴¹, the growth pattern of recurrent CRLM, defined as those
420 metastases that were not detectable by imaging before systemic treatment but appeared
421 during bevacizumab-chemotherapy, was compared with the growth pattern of metastases
422 that were already visible before systemic treatment. The recurrent metastases more often
423 demonstrated a replacement HGP when compared to the metastases that were already visible
424 before systemic treatment (80% versus 50%). In support of these observations, several
425 preclinical studies have demonstrated the switch from an angiogenic to a vessel co-opting
426 growth pattern associated with resistance to treatment with anti-VEGF drugs in several
427 malignancies. These include hepatocellular carcinoma⁵⁵, lung metastases of renal cell
428 carcinoma⁵⁶, brain metastases of melanoma⁵⁷ and glioblastoma⁵⁸.

429 Other studies^{59,60} found associations between systemic treatment of patients with CRLM and
430 histological characteristics that are highly suggestive of replacement growth. The so-called

431 'dangerous halo' consists of an irregular tumour-liver interface in a CRLM that was seen
432 selectively in patients that received chemotherapy before partial hepatectomy. Although
433 beyond the scope of the Mentha et al. study, the histological images in their report show that
434 the 'dangerous halo' consists of areas of replacement growth while the lesion without the
435 'dangerous halo' has a desmoplastic HGP (Figure 1 in Mentha et al. (2009)⁵⁹). Taken together,
436 the findings of Frentzas et al. (2016)⁴¹ and the reports on the 'dangerous halo'^{59,60} link the
437 replacement HGP to chemotherapy resistance with or without anti-VEGF treatment in
438 patients with liver metastatic colorectal cancer.

439 There are, however, studies suggesting that chemotherapy induces the desmoplastic growth
440 pattern in patients with replacement-type CRLM^{18,61}. Nierop and colleagues (2021)⁶¹ have
441 assessed the HGP of resected liver metastases in three cohorts of respectively 877, 1203 and
442 70 patients with CRC, respectively. The latter cohort was derived from a phase III clinical trial
443 in which patients were randomized between either peri-operative chemotherapy and
444 resection or resection only. In all three cohorts, the average presence of the desmoplastic HGP
445 at the tumour-liver interface was significantly higher in patients with pre-operative
446 chemotherapy compared to chemo-naïve patients (67% versus 43%, 63% versus 40%, and 61%
447 versus 33%, respectively ($p < 0.005$)). The fact that this shift in HGP was observed in a
448 randomised study is consistent with a lack of selection in the association of pre-operative
449 chemotherapy and the desmoplastic HGP. However, it remains to be determined whether
450 chemotherapy induces a transformation of replacement-type liver metastases into lesions
451 that form a desmoplastic rim or whether pre-existing desmoplastic lesions are more resistant
452 to chemotherapy.

453 Taken together, it appears that a transition from one HGP to another could occur in patients
454 with CRLM following systemic treatment. However, despite all the studies discussed above, a
455 reliable assessment in individual patients of the effect of systemic treatment on the HGPs of
456 liver metastases will only be possible when non-invasive imaging (as discussed below) or blood
457 analyses will be available to identify the HGPs at several time points during treatment. One
458 promising blood marker was recently proposed¹⁶. Circulating extracellular vesicles (EVs)
459 derived from patients with replacement-type CRLM exhibited significantly higher protein
460 expression of Claudin-2 relative to EVs isolated from patients with desmoplastic liver
461 metastases. Thus, high protein levels of Claudin-2 in EVs isolated in the blood circulation of
462 patients with liver metastatic CRC may predict the replacement HGP in CRLM.

463

464 **Standard method for assessment of the histopathological growth patterns of liver**
465 **metastases**

466 The updated consensus guidelines for tissue sampling of surgical liver resections and for
467 scoring and reporting of the HGPs of liver metastases are presented in Table 5. The proposed
468 sampling guidelines are not based on published experimental evidence but are rather an
469 empirical approach⁶². Given that the invasion front of liver metastases is often heterogeneous
470 in respect to HGPs, a balance must be struck between accurate assessment of growth patterns
471 and practical feasibility of sampling in a pathology laboratory. In addition, the sampling
472 procedure may be tumour-type dependent. For example, when dealing with CRLM, a two-
473 step approach can be envisaged for clinical routine, given that the presence of any proportion
474 of the interface with a non-desmoplastic HGP in any of the resected metastases has clear
475 prognostic significance^{18,19}. Initial sampling or scoring may consist of a limited number of
476 paraffin blocks and in the event that a region with a non-desmoplastic growth is identified in
477 the H&E-stained sections, the patient will be categorized into the corresponding HGP group.
478 In accordance with our proposed updated guidelines, additional and more extensive sampling
479 or scoring will only be necessary if no regions with non-desmoplastic growth are encountered
480 at initial sampling or scoring.

481 In reporting the HGPs of liver metastases, several factors will need to be considered. The
482 context of HGP assessment and the primary tumour type need to be considered because they
483 will determine how a patient will be categorised based on the liver metastasis HGP. For
484 example, for patients with CRLM, the HGP can provide prognostic information. For these
485 patients, categorization can, therefore, be based on the cut-off specified in the current
486 guidelines. For other primary tumour types, large studies that have defined a clinically
487 relevant cut-off value are still lacking and data reporting should be as precise as possible, in
488 order for the HGP-score to be available for future data analyses because predictive and
489 prognostic HGP cut-off values may be different for different primary tumour types.

490 There are essentially two ways to report HGPs when multiple metastases are resected. One
491 approach simply averages the scores for each HGP (desmoplastic, replacement, pushing)
492 across every available H&E-stained section for all the resected metastases. The other
493 approach uses an average of the scores for each HGP of all the available H&E-stained sections
494 for each individual metastasis separately and reports a score for every metastasis that has

495 been resected. The latter approach may be used when biological differences between
496 metastases are expected, for example related to a difference in response to pre-surgery
497 systemic treatment.

498 With the aim of identifying the presumed treatment-induced transition towards the
499 replacement HGP in future studies, we propose the following clinicopathological definition of
500 an ‘escape’ phenotype: ‘Liver metastases resected after pre-operative systemic treatment
501 combining signs of pathological response in the centre of the metastases while also exhibiting
502 at least a partly preserved desmoplastic rim and small peripheral areas of replacement-type
503 outgrowth or a complete halo of replacement growth’. Typically, these areas of replacement
504 growth do not show any of the characteristic signs of treatment response, as shown in
505 examples in Figure 3. Further information on the clinical value of this phenotype and its
506 biological underpinning will be derived from future studies on the HGPs of liver metastases.
507 We therefore propose to score the presence or absence of ‘escape’ in liver metastases that
508 are resected after administration of systemic pre-operative treatment.

509

510 **Immunohistochemical staining as an aid to scoring HGPs**

511 In some liver metastases, the histology is more complex, and this can result in a less
512 straightforward assessment of the HGPs. The ‘caveats’ are listed in the Table 5. Although the
513 assessment of HGPs of liver metastases is based exclusively on H&E-stained tissue sections,
514 additional immunohistochemical analyses may provide clarity when these challenging
515 conditions arise.

516 One example is the presence of an extensive immune cell infiltrate that obscures the tumour-
517 liver interface. In this case, the presence or absence of contact between tumour cells and
518 hepatocytes and the degree of hepatocyte co-option will determine whether the replacement
519 HGP must be considered. A double immunostaining approach coupling a hepatocyte marker
520 and a tumour cell marker can also be useful in such cases. For example, for liver metastases
521 from a colorectal carcinoma, the combination of antibodies directed against caudal type
522 homeobox 2 (CDX-2), cytokeratin (CK) 20 or CK19 (tumour cells) and Hepar-1, arginase1, or
523 CK18 (hepatocytes) can be used (Figure 4A). This immunostaining may also help to distinguish
524 a replacement HGP in which the liver cell plates are pushed away from the rare pushing HGP
525 (Figure 4B).

526 A second example where a clear-cut assessment of the HGP may be challenging is the
527 presence of a prominent ductular reaction at the tumour-liver interface. It can indeed be
528 difficult to distinguish cancer cells from cholangiocytes in this ductular reaction, especially
529 when nuclear pleomorphism of the cancer cells is limited and small aggregates or glandular
530 structures of cancer cells are formed. In addition, cancer cells and cholangiocytes can be
531 involved in common ductular structures. A possible solution is to combine cholangiocyte (CK7,
532 CK19 or carbohydrate antigen 19-9 (CA19-9)) and cancer cell markers (for CRLM, for example
533 CK20 or CDX-2) (Figure 4C) as an added tool for the analysis. Double immunostaining for
534 cancer cell and cholangiocyte markers can also be used to identify intrabiliary growth when
535 only a few cholangiocytes remain that are difficult to detect on an H&E-stained section (Figure
536 4D).

537

538

539 **Perspectives**

540 **Patient-derived xenograft models to study the HGPs of liver metastases**

541 The characterization of the distinct growth patterns using protein-based and genomic
542 approaches on surgically resected clinical specimens has begun to shed light on the underlying
543 biological processes that might drive the formation and growth of these lesions (Table 1).
544 However, the field currently lacks animal models that faithfully recapitulate the specific
545 histological features of these metastases (in particular desmoplastic metastases), necessary
546 for functional dissection of the molecular mediators that are currently only associated with
547 one type of lesion or the other.

548 To better understand the underlying biology of desmoplastic and replacement liver
549 metastases and to test therapeutic strategies tailored to these distinct lesions, it will be
550 important to develop PDXs that faithfully recapitulate the histological features seen in
551 patients. To this end, members of the Liver Metastasis Research Network at the Goodman
552 Cancer Institute (McGill University) and the McGill University Health Centre have developed a
553 patient-derived xenograft (PDX) pipeline where freshly resected CRLM, or biopsy samples,
554 from the operating theatre are brought immediately to the laboratory and are directly
555 implanted into the livers of SCID/beige mice¹⁶. The surgical specimen is divided into
556 approximately 1mm³ fragments, which are then carefully inserted into an incision made in the
557 left cardiac liver lobe of recipient mice. This approach has led to the successful establishment

558 of more than 30 PDX models that represent both replacement and desmoplastic lesions.
559 Importantly, a high degree of concordance (over 95%) between the HGPs of the metastases
560 that develop in the PDX models, when compared to the metastatic lesion in the patients from
561 which they were derived, has been achieved. In addition, organoids from these PDX models
562 have been generated (PDXOs) and propagated in culture (Tabariès S, Gregorieff A and Siegel
563 P, unpublished observations). When re-injected into the livers of mice, these PDXOs generate
564 desmoplastic or replacement lesions that recapitulate the HGP of the patient sample and PDX
565 model (Figure 5). While these models may provide useful information on the drivers
566 underlying specific HGPs, the lack of an adaptive immune response in the recipient mice, may
567 present a challenge to obtaining complete information on the associated immune
568 microenvironments. Although several methods have been described to generate so-called
569 'humanised mice', a less challenging approach is represented by the patient-derived explants
570 (PDE), ex vivo systems in which the in vivo tissue architecture and immune microenvironment
571 of human tumours can be maintained⁶³. These PDE platforms have been shown to be able to
572 predict clinical response to inhibitors of the PD-1-PD-L1 axis in patients with various types of
573 cancer⁶⁴ and might thus be used to study the biology of liver metastases with distinct HGPs.

574

575

576 **Automated scoring of HGPs of liver metastasis**

577 An increasing number of pathology laboratories are digitising glass slides into high-resolution
578 whole slide images (WSIs). This creates an opportunity to develop algorithms based on
579 machine learning and artificial intelligence that can extract clinically useful information from,
580 for example, WSIs of H&E-stained tumour sections. At least two teams have implemented this
581 approach to score the HGPs of liver metastases in an automated way.

582 The algorithm developed by Qianni Zhang and her team determines the relative contribution
583 of the replacement and of the desmoplastic HGP in a CRC liver metastasis, including the
584 proportion of the tumour-liver interface with 'uncertain' HGP²⁰. By combining image
585 processing and deep learning methods, they can achieve pixel level segmentation of the
586 tumour-liver interface. The algorithm is based on the accurate identification and
587 segmentation of the different tissue types at this interface by using deep neural networks and
588 by taking both cell and tissue characteristics into account. The neural network is employed to
589 identify the tissue type using patches of a certain size. The characterization of cell types within

590 these patches then adds sensitivity, especially at the transition of one tissue type to another.
591 In addition, uncertain regions are classified by analysing the similarity of this region and its
592 neighbour, a concept called ‘context-aware tissue region classification’. To train the model at
593 the tissue level, many patches were annotated by pathologists at the Karolinska University
594 Hospital, as belonging to liver parenchyma, fibrosis, necrosis, tumour, or inflammation. At the
595 cell level, the model was trained by pathologists to recognize hepatocytes, cells belonging to
596 fibrotic tissue, tumour cells and inflammatory cells. Once the algorithm succeeded in
597 accurately classifying the tissue types of an entire WSI, rules were developed to detect the
598 growth patterns based on the apposition of different types of tissue at the tumour-liver
599 interface: ‘liver-fibrosis-tumour’ for the desmoplastic HGP and ‘liver-tumour’ for the
600 replacement HGP. Extensive analytical and clinical validation is still ongoing.

601 The algorithm developed by Jeroen Van der Laak and his team was designed to distinguish
602 CRLM with 100% desmoplastic HGP from liver metastases with any proportion of non-
603 desmoplastic HGP by mimicking the visual feature extraction of an entire WSI at once, as done
604 by pathologists^{21,22}. Due to the extensive computational power required to process the
605 gigapixel WSIs at once, reduction of dimensionality (or compression) was necessary. This was
606 achieved by training an encoder in a supervised way to solve several representative tasks in
607 computational pathology. This encoder then reduced both the size and the noise level of the
608 WSIs. In a second step, a convolutional neural network was trained using the image-level
609 labels of ‘100% desmoplastic HGP’ and ‘any % of non-desmoplastic HGP’. When the algorithm
610 was applied to predict the HGP of CRLM, an AUC by ROC analysis of 0.895 was obtained. The
611 algorithm was also able to divide a cohort of 337 patients into two risk categories that
612 predicted OS (HR: 2.35, $p < 0.001$). It appears therefore that the HGP of liver metastases can
613 reliably be assessed through the compression and analysis of the WSIs of H&E-stained sections
614 and that this assessment has prognostic power.

615 These methods^{20,21} demonstrate the power of automated scoring algorithms to assist the
616 pathologist in collecting prognostic information based on parameters reflecting tumour
617 biology. Moreover, when these computer vision algorithms can directly learn from clinical
618 data such as survival, they will also be useful as a biomarker discovery tool²¹.

619

620 **Angiotropic extravascular migratory metastasis by pericytic mimicry**

621 Migration of cancer cells along blood vessels at and distal to the advancing front of primary
622 tumours and metastases has been extensively studied by the team of Lugassy and Barnhill,
623 particularly in melanoma (for review:³³). During this process of angiotropic extravascular
624 migration, cancer cells are in contact with endothelial cells ('angiotropism') via an amorphous
625 matrix that abundantly contains laminin and other constituents of the basement membrane,
626 thereby replacing the pericytes ('pericyte mimicry'). This type of extravascular migration has
627 been proposed as an alternative to the intravascular route of metastatic spread and seems to
628 be driven by cancer cells re-activating embryogenesis-like programs^{31,65}. In replacement-type
629 but not in desmoplastic liver metastases of melanoma, individual cancer cells can be observed
630 in the liver parenchyma disconnected and at a distance from the tumour-liver interface (Figure
631 6). As such, growth of liver metastases in a replacement pattern and extravascular migration
632 by angiotropism and pericytic mimicry can be regarded as complementary processes
633 representing a continuum of cancer progression with likely common underlying biological
634 mechanisms. To accurately detect extravascular migration of individual cancer cells in liver
635 metastases with a replacement growth pattern, immunohistochemical staining with cancer
636 cell-specific markers is necessary. Studies that quantify the extent of this angiotropic
637 extravascular migration in liver metastases are ongoing. It will be important to determine
638 whether the presence of angiotropic extravascular migration in liver metastases with a
639 replacement HGP contributes to a poorer outcome.

640

641 **Medical imaging as a tool to identify the HGPs of liver metastases**

642 The implementation of the HGPs in clinical practice will depend, in part, on creating the means
643 for recognising the growth patterns without the need for surgical removal of the liver
644 metastases and analysis by a pathologist. Medical imaging may be a promising approach to
645 solve this challenge. Indeed, several smaller studies suggest that CT and MRI images contain
646 information about the growth pattern (see Table 1 of previous guidelines manuscript by van
647 Dam P et al (2017)¹ and of the current guidelines)⁶⁶. This is not surprising, given the major
648 histological and biological differences between the desmoplastic and replacement growth
649 pattern. It is, however, only during the last few years that two teams have attempted to
650 identify growth patterns of liver metastases by medical imaging in a more systematic manner.
651 In Erasmus MC, Rotterdam, Starmans and colleagues have extracted more than 500 radiomics
652 features from CT-images of 76 patients with 93 CRC liver metastases with pure desmoplastic

653 (48%) or pure replacement (52%) HGP¹⁰. Importantly, these features were extracted from
654 entire metastases, not only from the lesion boundaries. A decision model based on the
655 selection of relevant features and classification of these features by machine learning had a
656 mean area under the curve of 0.69. Adding clinical information to the model did not improve
657 the power to predict the HGPs. Obviously, future studies will have to include metastases with
658 a mixed HGP. Nevertheless, this study is a valuable proof of concept for the utility of this
659 approach.

660 A team at the Peking University People's Hospital has recently published three studies on the
661 identification of HGPs of CRC liver metastases by medical imaging^{8,9,67}. It is important to note
662 that these studies attempt to identify the predominant growth pattern. Cheng and colleagues⁸
663 analysed contrast-enhanced CT-images of 126 CRC liver metastases, of which 68 had a
664 predominant (>50%) desmoplastic HGP and 58 had a predominant replacement HGP. Pre-
665 contrast and post-contrast CT-images (from both the arterial and portal venous phases) were
666 used. Of each of these 3 phases, 20 radiomics features were selected by an algorithm based
667 on minimal redundancy and maximal relevance. A fused decision-tree based signature of the
668 three phases resulted in a predictive model with an area under the curve of 0.94. Adding
669 clinical information or qualitative information provided by the radiologist did not improve the
670 predictive power.

671 In a similar study, MRI-derived regions, both covering the whole tumour volume as well as the
672 tumour-liver interface specifically, were subjected to radiomic feature extraction in a cohort
673 of 182 CRC liver metastases, of which 59 had a predominant (>50%) desmoplastic HGP and
674 123 had a predominant replacement HGP⁹. The predictive model that combined clinical
675 characteristics, qualitative imaging data generated by the radiologist and radiomic feature
676 data from the tumour-liver interface had an area under the curve of 0.91.

677 In their most recent study, the team at the Peking University People's Hospital has used their
678 CT-based radiomics HGP-signature to predict response and PFS in a cohort of 119 patients
679 with liver metastatic CRC treated with a combination of chemotherapy and bevacizumab⁶⁷.
680 Among 346 metastases studied, 206 had a radiological predominant desmoplastic HGP and
681 140 had a radiological predominant replacement HGP. Patients with only metastases with a
682 predominant desmoplastic HGP only as assessed by radiology had a significantly improved 1-
683 year PFS (HR = 0.34; p<0.001).

684 Although the studies by Cheng J et al (2019)⁸, Han Y et al (2020)⁹ and Wei S et al (2021)⁶⁷ are
685 very promising, validation of the results in larger cohorts by independent research teams and
686 with images acquired in different hospital is still necessary. In addition, at least for patients
687 with CRLM, it will be necessary to select, by means of imaging, those patients who have
688 metastases with a 100% desmoplastic growth pattern. So, even though considerable
689 progresses have been made to better determine the HGP prior to resection of the liver
690 metastases, there might still be a need to develop computational tools to integrate as many
691 parameters as feasible to stratify patients more accurately.

692

693 **Biology**

694 **New biological insights into growth patterns through immunohistochemical analyses**

695 Why does a liver metastasis in one patient develop a desmoplastic rim, while a metastasis in
696 a different patient has a replacement-type growth pattern, even when the primary tumour
697 type is the same? The full answer to this question and the biological mechanisms that underlie
698 the different growth patterns remain elusive. There are reasons to assume that cancer cell
699 motility and differentiation⁴¹, angiocrine signals⁶⁸ and interactions of cancer cells with
700 hepatocytes¹⁶ and with stromal and inflammatory cells³² are important factors regulating the
701 emergence of a distinct growth pattern. However, the precise mechanisms and the order of
702 events leading to the specific growth patterns remain unclear. There are compelling
703 observations to suggest that systemic treatment can alter the growth pattern^{41,61}. Also, given
704 that some mouse PDX models can recapitulate the pattern observed in the donor patient, the
705 growth pattern may be, at least in part, determined by cancer cell intrinsic properties¹⁶.
706 However, this does not exclude epigenetic control and the influence of tumour
707 microenvironment as important further mechanisms⁵².

708 Based on immunohistochemical stainings performed by the Karolinska team (Carlos
709 Fernández Moro, Marco Gerling, Béla Bozóky) to map the spatial relationships and phenotypic
710 states of epithelial and stromal cells, we propose two additional working hypotheses to
711 explain the biology of the HGPs.

712 A first working hypothesis is that the replacement growth pattern is the default pattern of
713 growth for cancer cells forming a tumour in the liver. This means that spontaneous or induced
714 transition to the desmoplastic pattern regularly takes place as a second step. An intrinsic and
715 important limitation of determining growth patterns by histological analysis of a resection

716 specimen is that we only get information from a single time point. A non-invasive method to
717 assess the HGPs, such as imaging, would allow longitudinal, repeated determination of HGPs.
718 We may, however, be able to infer information about the history of a liver metastasis by
719 comparing the centre of the tumour with its periphery. Surprisingly, after
720 immunohistochemical analysis, we found remnants of portal triads (branches of the bile duct
721 and of the hepatic artery) in the centre of both replacement and desmoplastic metastases.
722 These portal elements are regularly found to be embedded in specialized portal-type stromal
723 cells expressing Nerve Growth Factor Receptor (NGFR)- and alpha Smooth Muscle Actin
724 (alpha-SMA, Figure 7A). This observation supports a model in which the metastatic tumour
725 co-opts the sinusoidal blood vessels and the portal tract architecture of the liver, a mode of
726 growth that likely is advantageous, both for blood supply and structural support. While portal
727 triad co-option is readily identifiable at the tumour-liver interface of replacement-type liver
728 metastases, it may be more subtle in the fibrous rim of the desmoplastic type, where pre-
729 existing liver structures appear atrophic and attenuated. Here, immunohistochemistry can be
730 used to identify atrophic remnants of the portal triad. Together, this leads us to propose the
731 hypothesis that replacement growth, in most cases, precedes desmoplastic growth in
732 metastases with the latter HGP. The time point at which the growth patterns may switch and
733 the factors responsible for the proposed conversion remain unclear. There are other
734 observations to support a model in which replacement growth is the default growth pattern
735 of liver metastases. For example, when cancer cells spread within the bile ducts, the cancer
736 cells rest on the basement membrane of the normal biliary epithelial lining and progress by
737 replacing these normal cells and by co-opting the subepithelial stroma (Figure 7B). In addition,
738 we occasionally observe bile ducts as part of the ductular reaction in the desmoplastic rim, in
739 which cancer cells create hybrid cancer cell-cholangiocytes ductular structures (Figure 7C).
740 Although these histological observations need further validation and quantification, they do
741 support other observations consistent with growth pattern plasticity. Indeed, resistance to
742 chemotherapy can coincide with a switch to the replacement HGP^{41,59}, while pre-operative
743 chemotherapy converts metastases in some patients from replacement to desmoplastic
744 HGP⁶¹. Also, during disease progression in patients with recurrent colorectal liver metastases,
745 there is an evolution towards the more aggressive replacement HGP, as observed by analysing
746 repeated resections¹⁸.

747 A second working hypothesis is that the fibrous rim surrounding desmoplastic liver metastases
748 and the portal tract are biologically related. This hypothesis is supported by two observations.
749 *Firstly*, the stromal cells of the desmoplastic rim, and especially of the outer portion of the rim
750 neighbouring the surrounding liver parenchyma, strongly co-express NGFR and alpha-SMA,
751 indicative of a “myofibroblast” or “activated fibroblast” phenotype (Figure 7D). NGFR is
752 expressed by progenitors of Ito/stellate cells and of portal fibroblasts in the foetal liver^{69,70}
753 and this receptor also plays a crucial role during pathological liver fibrosis by inducing
754 fibrogenic gene expression, for example of the Transforming Growth Factor beta1-gene, in
755 activated (myo)fibroblasts⁷¹⁻⁷³. *Secondly*, by co-immunostaining for CK18, as a marker of
756 hepatocytes, and CK19, as a marker of cholangiocytes, we often observe mosaic ductular
757 structures in the desmoplastic rim composed of a mixture of cells with a hepatocyte-like and
758 a cholangiocyte-like phenotype (Figure 7E). Activated fibroblasts are known to induce
759 cholangiocyte differentiation in hepatic stem-like cells (for example, via Jagged-1 and
760 Hedgehog ligands) and this process partly relies on NGFR expression in the activated liver
761 fibroblasts^{73,74}. NGFR-expressing and activated, alpha-SMA-positive fibroblasts in the
762 desmoplastic rim may therefore activate extracellular matrix production and induce a ductular
763 reaction by engaging bipotent progenitors, resembling portal tract development as well as
764 liver fibrosis in other pathological conditions involving liver injury⁷⁵. In the metastasis context,
765 destruction of liver cells by the invading tumour, inflammation, and damage of the
766 peritumoral liver tissue are potential mechanisms of liver injury.

767

768 **Hypotheses to explain the biology of the distinct histopathological growth patterns**

769 There is currently no satisfactory explanation for the specific biology of each of the
770 histopathological growth patterns. Table 6 therefore summarizes some hypotheses to explain
771 the distinct phenotypes of the desmoplastic and replacement growth patterns. These
772 hypotheses are derived from histopathological insights, pre-clinical animal models and the
773 comparison with organ development in the embryo. The hypotheses listed in Table 6 are not
774 mutually exclusive and elements of each probably contribute to the specific growth patterns
775 of liver metastases. In addition, some hypotheses outlined only address individual growth
776 patterns.

777 Taken together, cancer cells within a liver metastasis exhibiting a replacement growth pattern
778 appear to adapt to the microenvironment of the liver parenchyma and may therefore be

779 sensitive to a liver pro-metastatic reaction of the patient⁷⁶, while cancer cells of a desmoplastic
780 metastasis create their own microenvironment. Against this background, it could be argued
781 that cancer cells in a replacement metastasis behave like hepatocytes or hepatocyte
782 progenitor cells communicating with the liver niche (for example with the co-opted sinusoidal
783 endothelial cells), whereas cancer cells in a desmoplastic metastasis more autonomously form
784 a tumour that resembles the primary tumour. The plasticity of the growth patterns suggested
785 by clinical observations appears to indicate that this divergent behaviour of cancer cells in the
786 liver is not, or at least not entirely, the result of a different mutational gene profile, but rather
787 of epigenetic events and the ability to respond to stimuli from the microenvironment, such as
788 soluble factors elicited by the liver pro-metastatic reaction⁷⁶ and liver immune responses⁷⁷.

789

790

791 Discussion

792 Since the publication of the first consensus guidelines¹, numerous studies have been
793 conducted describing the impact of HGPs on the outcome of patients with liver metastases
794 (Table 1). These studies are not limited to liver metastases from colorectal carcinoma, but also
795 include patients with liver metastases from breast carcinoma, melanoma, and pancreatic
796 adenocarcinoma^{5,42,44,45}. The association between replacement HGP and poorer patient
797 outcome, independent of the primary tumour type, has been confirmed by these new studies.
798 A new cut-off to categorize patients with CRLM according to the HGPs is presented in the
799 current guidelines. This cut-off is derived from the observation in a large multi-centre cohort
800 of patients that any proportion of non-desmoplastic HGP, however small, is associated with a
801 worse prognosis. The extent of non-desmoplastic features within the metastases in itself does
802 not seem to modulate outcome any further. We have therefore updated the guidelines for
803 scoring the HGPs of CRLM for the purposes of prognostication of patients, and we propose
804 herein some immunohistochemical assays that may help to identify the growth patterns in
805 more challenging situations, such as in the presence of dense inflammation or systemic
806 treatment effects.

807 The tumour-type independent prognostic value of the HGPs fuels the idea that the biology of
808 the replacement HGP is fundamentally different from that of the desmoplastic growth
809 pattern. Some of these differences have been well described. In the desmoplastic growth
810 pattern, a dense immune-inflammatory cell infiltrate surrounds the fibrous rim, while the

811 replacement growth pattern has the characteristics of an immune desert, especially when no
812 chemotherapy is involved^{2-4,32,78}. The desmoplastic pattern has angiogenic vascular hot spots
813 in between cancer cell nests and hypoxic areas while the replacement growth pattern shows
814 a uniformly high vessel density and minimal hypoxia, probably because of efficient vessel co-
815 option^{30,38,41}. Consequently, replacement-type liver metastases are also metabolically more
816 active than desmoplastic liver metastases, as demonstrated by FDG-PET analyses⁷⁹.

817 A striking morphological difference between the growth patterns lies in the organisation of
818 the cancer cells and the interaction with the host liver tissue. In replacement-type liver
819 metastases, cancer cells mimic hepatocytes by an arrangement in solid cell plates in between
820 the co-opted sinusoidal blood vessels. This type of growth clearly resembles the ‘vascularizing
821 organogenesis’ that takes place when the liver develops in the embryo and may also be guided
822 by instructive signals originating in the liver sinusoidal endothelial cells⁸⁰⁻⁸³. Accordingly,
823 cancer cells belonging to replacement-type liver metastases seem to hijack the embryological
824 program of liver development with the resulting tumour adopting the histological architecture
825 of liver tissue. The work of Teng and team⁵² supports this hypothesis. They have shown that
826 CRLM, when compared with primary colorectal cancer, simultaneously gain liver-specific and
827 lose colon-specific transcription programs. They also showed that this is the result of a
828 reprogrammed enhancer landscape. Enhancers are regulatory elements in the genome that
829 are influenced by the environment and, as such, play an important role in tissue-specific gene
830 expression patterns and cell identity. However, whether differences in the enhancer
831 landscape can also explain the morphological differences between the replacement and the
832 desmoplastic growth pattern of liver metastases still needs to be investigated. During
833 desmoplastic growth of liver metastases, the cancer cells arrange in more differentiated
834 structures, not as cancer cell plates, and resemble the glandular structures of primary
835 colorectal and breast cancer. In other words, desmoplastic liver metastases morphologically
836 mimic the primary tumour they originate from, where cancer cells typically induce a
837 continuous wound-healing response with inflammation, fibrosis, coagulation, and
838 angiogenesis. This probably involves tumour-host interactions that are active in the primary
839 tumour and epithelial-stromal interactions of the normal tissue counterpart (e.g., colon,
840 breast, etc.). These hypothetical and morphology-driven views on the divergent biological
841 mechanisms of the liver metastasis growth patterns are now being investigated by bulk RNA-
842 sequencing, single cell RNA-sequencing, in situ RNA-sequencing and multiplex

843 immunohistochemistry. PDX-models and co-organoids derived from patient liver metastases
844 are used for functional validation. Alternative hypotheses to explain the distinct
845 histopathological growth patterns have been listed in Table 6.

846 At a single time-point, patients often have liver metastases consisting of both desmoplastic
847 and replacement HGP regions. This is, for example, true for about 60% of all patients with
848 resected CRLM¹⁸, independent of whether chemotherapy was administered before surgery.
849 Co-occurrence of distinct HGPs thus seems to be part of the growth process of liver metastases
850 and this may be the consequence of transitioning from one HGP to another. We now propose
851 the working hypothesis, based on immunohistochemical analyses, that the replacement HGP
852 is the default growth pattern of liver metastases. Although there are data to support the view
853 that pre-surgery chemotherapy can induce desmoplastic growth in some metastases^{18,61} and
854 that a switch to replacement growth can occur upon resistance to systemic treatment⁴¹, the
855 cellular and molecular mechanisms responsible for these transitions from one growth pattern
856 to another remain to be elucidated. What these and other findings do seem to suggest is that
857 epigenetic processes drive the growth patterns rather than mutational hardwiring. Recently,
858 the concept of ‘histostasis’, driven by cancer cell-autonomous properties, has been put
859 forward to explain the morphological resemblance between metastatic tissue and the
860 corresponding primary tumour⁸⁴. As a complement, we propose here to introduce the concept
861 of ‘histokinesis’, a process driven by cancer cell-responsiveness to instructive host tissue-
862 derived signals, such as the pro-metastatic liver reaction⁷⁶, to explain the clear morphological
863 differences between the primary tumour and, for example, replacement-type liver
864 metastases. This is probably a more general biological concept, given the observations of
865 similar growth patterns in, for example, lung metastases^{56,85-87}.

866 The plasticity of the growth patterns might be exploited in future therapeutic strategies. A
867 prerequisite to feasibility would be a continuous evaluation of the growth pattern in a pre-
868 surgical setting of systemic treatment. This implies a reliable non-invasive method for
869 repeatedly identifying the growth patterns during the patient treatment. Table 1 highlights
870 the initiatives of several teams worldwide to develop algorithms to assess the growth patterns
871 of liver metastases by medical imaging^{8-10,66}. In addition, several studies are still ongoing with
872 results to be expected in the coming years. As an alternative, circulating markers in the blood
873 of patients may be useful to identify the prevailing growth pattern at a certain moment in

874 time. A study by Tabariès¹⁶ proposes exosome-derived claudin-profiling as a tool to predict
875 the growth pattern of CRLM.

876 The role of systemic treatment, either neo-adjuvant or adjuvant, for patients with a priori
877 resectable metachronous CRLM remains unclear. In many countries, patients will receive
878 standard post-operative chemotherapy, following metastasectomy performed with curative
879 intent. Although the benefit of adjuvant treatment is still to be fully appreciated, surgery alone
880 is often not considered. To face the problem of potentially low accrual in a study that
881 compares surgery alone with surgery combined with adjuvant chemotherapy, we suggest
882 limiting the study population to those patients with liver metastases that exclusively have the
883 desmoplastic growth pattern upon careful pathological evaluation of the resected metastases,
884 as a first approach. Alternatively, and only when a non-invasive pre-operative marker of the
885 HGPs becomes available (as liver biopsies to evaluate the HGP are not suitable), a window of
886 opportunity study could be envisioned to examine the role of specific treatments for
887 replacement and desmoplastic liver metastases in patients with (borderline) resectable liver
888 metastases. For example, given the distinct immune contexture of each of the growth
889 patterns, the choice of immunotherapy may need to be adapted to the growth pattern of the
890 liver metastases. It is also unclear whether the clinically relevant systemic immunosuppressive
891 effects of the presence of liver metastases, leading to reduced benefit from immune
892 checkpoint inhibitors, may be growth pattern-dependent⁸⁸. A better insight into the
893 interaction of liver-metastatic cancer cells with the complex immune environment of the liver
894 will contribute to understanding the biology of the HGPs⁷⁷.

895 In conclusion, we provide updated guidelines for scoring the histopathological growth
896 patterns of liver metastases. These are of importance not only to implement the HGPs in the
897 clinical care of patients with liver metastatic cancer, but also to properly conduct studies that
898 seek to identify the biological basis for these growth patterns. The latter is important to better
899 understand the heterogeneity of liver metastases, and thus perhaps also of tumour expansion
900 in other organs where similar growth patterns have been described, such as in the lungs^{56,87}.

901

902

903

904

905 **Figure and table legends**

906 Figure 1. The histopathological growth patterns of liver metastases (H&E images). (A) Low
907 magnification image of a CRC liver metastasis with a desmoplastic HGP. (B) & (C) Higher
908 magnification of the tumour-liver interface of CRC liver metastases with a desmoplastic HGP.
909 The blue double headed arrow indicates the desmoplastic rim that separates the carcinoma
910 from the liver parenchyma. The green arrowheads indicate the immune cell infiltrate which is
911 typically located at the transition between the desmoplastic rim and the liver parenchyma.
912 The tumours show glandular differentiation and cell detritus in the lumina of these glandular
913 structures, reminiscent of the histology of a primary CRC (white arrowheads). (D) Low
914 magnification image of a CRC liver metastasis with a replacement HGP. The green arrowheads
915 indicate the tumour-liver interface. There is no glandular differentiation: cancer cells from
916 solid nests and trabeculae. (E) & (F) Higher magnification of the tumour-liver interface of CRC
917 liver metastases with a replacement HGP. The green arrowheads indicate contact between
918 cancer cells and hepatocytes. In (E), cancer cells form cell plates that are in continuity with the
919 liver cell plates. A co-opted sinusoidal blood vessel is marked by the blue arrowheads. In (F),
920 the liver cell plates are pushed aside but cancer cells are still in contact with hepatocytes while
921 invading into these liver cell plates (green arrowheads). (G) Low magnification image of a CRC
922 liver metastasis with a pushing HGP. (H) On higher magnification, a sharp tumour-liver
923 interface is noticed without desmoplastic rim and without cancer cells invading into the liver
924 parenchyma. Often metastases with a pushing HGP produce mucin, as shown in this example.
925 (I) Lobular breast carcinoma liver metastasis with a sinusoidal HGP (autopsy case). Cancer cells
926 are located within the lumen of sinusoidal blood vessels (green asterisks), in between liver cell
927 plates (blue asterisks). Red blood cells are intermingled with the cancer cells (blue
928 arrowheads). (J) Low magnification image of intrabiliary tumour growth (CRC) in a portal tract.
929 The structures constituting a portal tract are present: artery branches (A), vein branch (V),
930 nerve bundle (N), and branches of the bile duct (B), in this case filled with cancer cells. (K)
931 Higher magnification of the left bile duct branch of image J. The normal bile duct epithelium
932 (blue arrowheads) is still present but is replaced by cancer tissue that fills the lumen of the
933 bile duct branch.

934

935 Figure 2. Kaplan–Meier curves depicting overall and disease-free survival of patients with
936 colorectal liver metastases, stratified by the new cut-off for histopathological growth patterns

937 categorisation (A to D) and by the predominant growth pattern (E and F). N = 1931 patients
938 with resected colorectal liver metastases.

939

940 Figure 3. H&E image of the escape phenotype. (A) Low magnification image with large necrotic
941 areas in the centre of the CRC liver metastasis, remnants of the desmoplastic rim (d) and vital
942 replacement-type outgrowth at the tumour-liver interface (arrows). (B) Higher magnification
943 of the 'escape' area with replacement HGP. Li, liver; Me, metastatic tumour tissue.

944

945 Figure 4. Immunohistochemical staining as an aid to HGP scoring

946 A. Detection of the replacement HGP in the presence of an extensive immune cell infiltrate
947 that obscures the tumour-liver interface by identification of cancer cell-hepatocyte contact
948 (green arrowheads) at the tumour-liver interface and co-option of hepatocytes (blue
949 arrowheads) in liver lobules undergoing replacement by cancer cells. CK19 (DAB, brown) stains
950 colorectal cancer cells. CK18 (AP, red) stains hepatocytes. Left: low magnification; Right: high
951 magnification.

952 B. Detection of the pushing-type replacement (type 2) HGP in which the hepatocyte plates are
953 slender (yellow dotted area) and arranged in parallel with the tumour-liver interface. Green
954 arrowheads indicate cancer cell-hepatocyte contact and blue arrowheads hepatocyte co-
955 option. CK19 (DAB, brown) stains colorectal cancer cells. CK18 (AP, red) stains hepatocytes.

956 C. Prominent ductular reaction at the tumour-liver interface in the desmoplastic HGP. Areas
957 of ductular reaction (green arrowheads) are present in the outer region of the fibrous rim
958 (green dotted region). Cancer cells are (blue arrow) identified in the metastasis centre,
959 adjacent to necrotic areas (orange star). Right. Detail of the ductular reaction at the tumour-
960 liver interface. Cholangiocytes (CK7+) form irregular, angulated, anastomosing ductuli. Note
961 the presence of interspersed cancer cells (CK20+, blue arrows) within the ductuli, forming
962 common ductular structures. CK20 (DAB, brown) stains colorectal cancer cells. CK7 (AP, red)
963 stains cholangiocytes.

964 D. Detection of intrabiliary tumour growth. A discontinuous lining of biliary epithelial cells
965 (blue arrows) can be identified surrounding colorectal cancer cells (sparsely positive for CK20
966 in this case) with focal contact between colorectal cancer cells and biliary epithelial cells
967 (green stars). CK20 (DAB, brown) stains colorectal cancer cells. CK7 (AP, red) stains
968 cholangiocytes. Left: low magnification; right: high magnification.

969

970 Figure 5.

971 Patient-derived xenograft (PDX) mice models for CRC liver metastases with a desmoplastic
972 and a replacement HGP (H&E images).

973 A. Resected liver metastasis with a desmoplastic HGP (Left) and corresponding xenograft PDX-
974 model (Right). Green arrows indicate the desmoplastic rim in the patient sample and in the
975 liver metastasis of the mouse (PDX#35, see supplementary table 2 in Tabariès S, 2021)¹⁶.

976 B. Resected liver metastasis with a replacement HGP (Left) and corresponding xenograft PDX-
977 model (Right). Green arrows indicate some of the areas in which the cancer cells grow into
978 the liver cell plates and contact the hepatocytes, both in the patient sample and in the liver
979 metastasis of the mouse (PDX#30, see supplementary table 2 in Tabariès S, 2021)¹⁶.

980

981 Figure 6. Images of melan-A immunostaining of melanoma liver metastases. (A) High
982 magnification images of the tumour-liver interface of a melanoma liver metastasis with a
983 replacement HGP. Small groups of melanoma cells and individual melanoma cells have
984 migrated away from the tumour-liver interface (arrows). (B) High magnification images of the
985 tumour-liver interface of a melanoma liver metastasis with a desmoplastic HGP. No migration
986 of melanoma cells in the desmoplastic rim, marked by 'D'.

987

988 Figure 7. New biological insights into growth patterns through immunohistochemical analyses

989 A. Remnants of portal zones in the centre of colorectal liver metastases. Left. Detail of a
990 tumour centre in a metastasis with a predominant replacement HGP showing remnant of a
991 portal zone with bile duct (green arrowhead) and hepatic artery branch (blue arrowhead).
992 Note colonization by viable cancer cells of the periportal limiting plate region (orange
993 arrowhead). Caldesmon (DAB, brown) stains smooth muscle cells, mainly in the media layer
994 of the hepatic artery. CK7 (DAB, brown) stains bile duct epithelium. CD34 (AP, red) stains the
995 endothelium of the hepatic artery and of the stromal capillary network. Right. Tumour centre
996 in a metastasis with a desmoplastic HGP showing multiple remnants of portal zones between
997 lobules that have undergone complete replacement by cancer cells (orange arrowheads). The
998 bile ducts (green arrows) and branches of the hepatic artery (blue arrows) are embedded in
999 NGFR+ portal stroma (yellow arrowheads). CD146 (DAB, brown) stains smooth muscle cells

1000 (mainly in the wall of hepatic arteries) and areas of ductular reaction. NGFR (AP, red) stains
1001 activated portal fibroblasts and stellate cells.

1002 B. Intrabiliary tumour growth in a CRC liver metastasis. Left. Densely packed cancer cells
1003 (green stars) show exophytic growth and fill the bile duct lumen. Portions of preserved biliary
1004 epithelium (blue arrows) are still identified. Right. Detail illustrating the replacement-like
1005 growth of cancer cells, which progress by establishing direct contact with and replacing the
1006 cholangiocytes while co-opting their basal membrane. CK20 (DAB, brown) stains colorectal
1007 cancer cells. CK7 (AP, red) stains cholangiocytes.

1008 C. Hybrid cancer cell-cholangiocyte ductular structures. Ductular reaction in the desmoplastic
1009 rim with cancer cells (CK20-positive, DAB, brown) forming hybrid structures with
1010 cholangiocytes (CK7-positive, AP, red).

1011 D. Stromal cell heterogeneity in a metastasis with a desmoplastic HGP. Top. The outer region
1012 of the desmoplastic rim stains strongly positively for NGFR (Left, green arrows) and α -smooth
1013 muscle actin (alpha-SMA) (Right, green arrowheads), consistent with activated portal/stellate
1014 cell stroma. In contrast, the stroma in the metastasis centre is positive for alpha-SMA but
1015 negative for NGFR, indicating a desmoplastic character (Left and right, blue arrows). Bottom.
1016 Reference illustrations of activated portal stroma in non-neoplastic liver, showing (Left) NGFR
1017 and (Right) alpha-SMA immunoreactivity (Left and right, green arrows). CD146 (DAB, brown)
1018 stains vascular and sinusoidal endothelium and smooth muscle in branches of the hepatic
1019 artery and portal vein. NGFR (AP, red) stains activated portal fibroblasts and stellate cells.
1020 CK18 (DAB, brown) stains hepatocytes and cholangiocytes. Alpha-SMA (AP, red) stains
1021 activated portal fibroblasts, stellate cells and desmoplasia-associated myofibroblasts.

1022 E. Ductular reaction in the desmoplastic rim with cells with a hepatocyte-like (CK18-positive,
1023 AP, red) and a cholangiocytes-like (CK18, DAB, brown) phenotype (green arrows).

1024

1025

1026 Table 1. Overview of studies on the histopathological growth patterns of liver metastases, in
1027 addition to the studies listed in table 1. of the first guidelines paper (Van Dam et al 2017).

1028 Abbreviations: CGH = comparative genomic hybridization; CRC = colorectal cancer; CRISPR =
1029 clustered regularly interspaced short palindromic repeats; CT = computed tomography; DFS =
1030 disease-free survival; dHGP = desmoplastic histopathological growth pattern; EMT =
1031 epithelial-to-mesenchymal transition; H&E = haematoxylin-and-eosin stained; HGP =

1032 histopathological growth pattern; HR = hazard's ratio; MMP = matrix metalloprotease; MRI =
1033 magnetic resonance imaging; mCRS = metabolic clinical risk score; NOD scid = nonobese
1034 diabetic severe combined immunodeficiency; MMPI = macro-metastasis/organ parenchyma
1035 interface; OS = overall survival; PFS = progression-free survival; PDX = patient-derived
1036 xenograft; RFS = relapse free survival; rHGP = replacement histopathological growth pattern;
1037 ROI = region of interest; TLI = tumour-liver interface; VEGF = vascular endothelial growth
1038 factor; WES = whole exome sequencing.

1039

1040 Table 2. Key histopathological characteristics of the growth patterns of liver metastases.

1041

1042 Table 3. Clinicopathological baseline and treatment characteristics of the cohort of 1931
1043 patients used to evaluate the impact on outcome of the new cut-off for patient categorisation
1044 according to the histopathological growth pattern of resected colorectal liver metastases.

1045 Abbreviations: ASA = American Society of Anaesthesiologists; CEA = carcinoembryonic
1046 antigen; CRLM = colorectal liver metastasis; Erasmus MC = Erasmus Medical Center Cancer
1047 Institute; IQR = interquartile range; MSKCC = Memorial Sloan Kettering Cancer Center;
1048 Radboud UMC = Radboud University Medical Center.

1049

1050 Table 4. Overall and disease-free survival estimates for different histopathological growth
1051 pattern cut-offs in 1931 patients treated with curative intent resection for colorectal liver
1052 metastases.

1053 Abbreviations: ASA = American Society of Anaesthesiologists; CEA = carcinoembryonic
1054 antigen; CRLM = colorectal liver metastasis; HGP = histopathological growth pattern; NA = not
1055 available.

1056

1057 Table 5. Updated standard method for histopathological growth pattern assessment of liver
1058 metastases.

1059

1060 Table 6. Hypotheses to explain the biology of the different histopathological growth patterns
1061 of liver metastases, including supporting evidence and/or supporting arguments.

1062

1063

1064

1065 References

- 1066 1. van Dam, P.J., van der Stok, E.P., Teuwen, L.A., Van den Eynden, G.G., Illemann, M.,
1067 Frentzas, S. et al. International consensus guidelines for scoring the histopathological
1068 growth patterns of liver metastasis. *Br J Cancer* **117**, 1427-1441 (2017).
- 1069 2. Stremitzer, S., Vermeulen, P., Graver, S., Kockx, M., Dirix, L., Yang, D. et al. Immune
1070 phenotype and histopathological growth pattern in patients with colorectal liver
1071 metastases. *Br J Cancer* **122**, 1518-1524 (2020).
- 1072 3. Liang, J.Y., Xi, S.Y., Shao, Q., Yuan, Y.F., Li, B.K., Zheng, Y. et al. Histopathological growth
1073 patterns correlate with the immunoscore in colorectal cancer liver metastasis patients
1074 after hepatectomy. *Cancer Immunol Immunother* **69**, 2623-2634 (2020).
- 1075 4. Hoppener, D.J., Nierop, P.M.H., Hof, J., Sideras, K., Zhou, G., Visser, L. et al. Enrichment
1076 of the tumour immune microenvironment in patients with desmoplastic colorectal
1077 liver metastasis. *Br J Cancer* **123**, 196-206 (2020).
- 1078 5. Watanabe, K., Mitsunaga, S., Kojima, M., Suzuki, H., Irisawa, A., Takahashi, H. et al. The
1079 "histological replacement growth pattern" represents aggressive invasive behavior in
1080 liver metastasis from pancreatic cancer. *Cancer Med* **9**, 3130-3141 (2020).
- 1081 6. Messaoudi, N., Henault, D., Stephen, D., Cousineau, I., Simoneau, E., Rong, Z. et al.
1082 Prognostic implications of adaptive immune features in MMR-proficient colorectal
1083 liver metastases classified by histopathological growth patterns. *Br J Cancer* (2022).
- 1084 7. Gulia, S., Khurana, S., Shet, T. & Gupta, S. Radiographically occult intrasinusoidal liver
1085 metastases leading to hepatic failure in a case of breast cancer. *BMJ Case Rep* **2016**,
1086 (2016).
- 1087 8. Cheng, J., Wei, J., Tong, T., Sheng, W., Zhang, Y., Han, Y. et al. Prediction of
1088 Histopathologic Growth Patterns of Colorectal Liver Metastases with a Noninvasive
1089 Imaging Method. *Ann Surg Oncol* **26**, 4587-4598 (2019).
- 1090 9. Han, Y., Chai, F., Wei, J., Yue, Y., Cheng, J., Gu, D. et al. Identification of Predominant
1091 Histopathological Growth Patterns of Colorectal Liver Metastasis by Multi-Habitat and
1092 Multi-Sequence Based Radiomics Analysis. *Front Oncol* **10**, 1363 (2020).
- 1093 10. Starmans, M.P.A., Buisman, F.E., Renckens, M., Willemsen, F., van der Voort, S.R.,
1094 Groot Koerkamp, B. et al. Distinguishing pure histopathological growth patterns of
1095 colorectal liver metastases on CT using deep learning and radiomics: a pilot study. *Clin
1096 Exp Metastasis* **38**, 483-494 (2021).
- 1097 11. Alzubi, M.A., Sohal, S.S., Sriram, M., Turner, T.H., Zot, P., Idowu, M. et al. Quantitative
1098 assessment of breast cancer liver metastasis expansion with patient-derived
1099 xenografts. *Clin Exp Metastasis* **36**, 257-269 (2019).
- 1100 12. Piquet, L., Dewit, L., Schoonjans, N., Millet, M., Berube, J., Gerges, P.R.A. et al. Synergic
1101 Interactions Between Hepatic Stellate Cells and Uveal Melanoma in Metastatic
1102 Growth. *Cancers (Basel)* **11**, (2019).
- 1103 13. Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernandez-Mateos, J., Khan, K. et
1104 al. Patient-derived organoids model treatment response of metastatic gastrointestinal
1105 cancers. *Science* **359**, 920-926 (2018).
- 1106 14. Ibrahim, N.S., Lazaris, A., Rada, M., Petrillo, S.K., Huck, L., Hussain, S. et al.
1107 Angiopoietin1 Deficiency in Hepatocytes Affects the Growth of Colorectal Cancer Liver
1108 Metastases (CRCLM). *Cancers (Basel)* **12**, (2019).
- 1109 15. Masaki, S., Hashimoto, Y., Kunisho, S., Kimoto, A. & Kitadai, Y. Fatty change of the liver
1110 microenvironment influences the metastatic potential of colorectal cancer. *Int J Exp
1111 Pathol* **101**, 162-170 (2020).

- 1112 16. Tabaries, S., Annis, M.G., Lazaris, A., Petrillo, S.K., Huxham, J., Abdellatif, A. et al.
1113 Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the
1114 replacement type growth pattern. *Commun Biol* **4**, 657 (2021).
- 1115 17. Bartlett, A.Q., Pennock, N.D., Klug, A. & Schedin, P. Immune Milieu Established by
1116 Postpartum Liver Involution Promotes Breast Cancer Liver Metastasis. *Cancers (Basel)*
1117 **13**, (2021).
- 1118 18. Galjart, B., Nierop, P.M.H., van der Stok, E.P., van den Braak, R., Hoppener, D.J.,
1119 Daelemans, S. et al. Angiogenic desmoplastic histopathological growth pattern as a
1120 prognostic marker of good outcome in patients with colorectal liver metastases.
1121 *Angiogenesis* **22**, 355-368 (2019).
- 1122 19. Hoppener, D.J., Galjart, B., Nierop, P.M.H., Buisman, F.E., van der Stok, E.P., Coebergh
1123 van den Braak, R.R.J. et al. Histopathological Growth Patterns and Survival After
1124 Resection of Colorectal Liver Metastasis: An External Validation Study. *JNCI Cancer*
1125 *Spectr* **5**, pkab026 (2021).
- 1126 20. Zhaoyang, X., Carlos Fernández, M., Danyil, K., Béla, B., Le, D. & Qianni, Z., *Tissue Region*
1127 *Growing for Hispathology Image Segmentation*, in *Proceedings of the 2018 3rd*
1128 *International Conference on Biomedical Imaging, Signal Processing*. 2018, Association
1129 for Computing Machinery: Bari, Italy.
- 1130 21. Tellez, D., Höppener, D., Verhoef, C., Grünhagen, D., Nierop, P., Drozdal, M. et al.
1131 *Extending unsupervised neural image compression with supervised multitask learning*.
1132 in *Medical Imaging with Deep Learning*. 2020. PMLR.
- 1133 22. Tellez, D., Litjens, G., van der Laak, J. & Ciompi, F. Neural Image Compression for
1134 Gigapixel Histopathology Image Analysis. *IEEE Trans Pattern Anal Mach Intell* **43**, 567-
1135 578 (2021).
- 1136 23. Nierop, P.M.H., Galjart, B., Hoppener, D.J., van der Stok, E.P., Coebergh van den Braak,
1137 R.R.J., Vermeulen, P.B. et al. Salvage treatment for recurrences after first resection of
1138 colorectal liver metastases: the impact of histopathological growth patterns. *Clin Exp*
1139 *Metastasis* **36**, 109-118 (2019).
- 1140 24. Nierop, P.M.H., Hoppener, D.J., van der Stok, E.P., Galjart, B., Buisman, F.E.,
1141 Balachandran, V.P. et al. Histopathological growth patterns and positive margins after
1142 resection of colorectal liver metastases. *HPB (Oxford)* **22**, 911-919 (2020).
- 1143 25. Buisman, F.E., Van der Stok, E.P., Galjart, B., Vermeulen, P.B., Balachandran, V.P.,
1144 Coebergh van den Braak, R.R.J. et al. Histopathological growth patterns as biomarker
1145 for adjuvant systemic chemotherapy in patients with resected colorectal liver
1146 metastases. *Clin Exp Metastasis* (2020).
- 1147 26. Masson, P. Les tumeurs. *Traité De Pathologie Et Thérapie Appliquées* **27**, 572-574
1148 (1923).
- 1149 27. Hamperl, H. Die morphologie der tumoren. *Lehrbuch Der Allgemeinen Pathologie Und*
1150 *Der Pathologischen Anatomie* **6**, 243-244 (1956).
- 1151 28. Elias, H. & Bouldin, R.F. Reaction of the normal liver parenchyma to metastatic
1152 carcinoma. *Acta Hepatosplenol* **9**, 357-386 (1962).
- 1153 29. Elias, H., Bierring, F. & Grunnet, I. Cellular Changes in the Vicinity of Metastatic
1154 Carcinoma, Observed by Light and Electron Microscopy. *Oncologia* **18**, 210-24 (1964).
- 1155 30. Vermeulen, P.B., Colpaert, C., Salgado, R., Royers, R., Hellemans, H., Van Den Heuvel,
1156 E. et al. Liver metastases from colorectal adenocarcinomas grow in three patterns with
1157 different angiogenesis and desmoplasia. *J Pathol* **195**, 336-42 (2001).

- 1158 31. Latacz, E., Caspani, E., Barnhill, R., Lugassy, C., Verhoef, C., Grunhagen, D. et al.
1159 Pathological features of vessel co-option versus sprouting angiogenesis. *Angiogenesis*
1160 **23**, 43-54 (2020).
- 1161 32. van Dam, P.J., Daelemans, S., Ross, E., Waumans, Y., Van Laere, S., Latacz, E. et al.
1162 Histopathological growth patterns as a candidate biomarker for immunomodulatory
1163 therapy. *Semin Cancer Biol* **52**, 86-93 (2018).
- 1164 33. Lugassy, C., Kleinman, H.K., Vermeulen, P.B. & Barnhill, R.L. Angiotropism, pericytic
1165 mimicry and extravascular migratory metastasis: an embryogenesis-derived program
1166 of tumor spread. *Angiogenesis* **23**, 27-41 (2020).
- 1167 34. Allison, K.H., Fligner, C.L. & Parks, W.T. Radiographically occult, diffuse intrasinusoidal
1168 hepatic metastases from primary breast carcinomas: a clinicopathologic study of 3
1169 autopsy cases. *Arch Pathol Lab Med* **128**, 1418-23 (2004).
- 1170 35. Simone, C., Murphy, M., Shifrin, R., Zuluaga Toro, T. & Reisman, D. Rapid liver
1171 enlargement and hepatic failure secondary to radiographic occult tumor invasion: two
1172 case reports and review of the literature. *J Med Case Rep* **6**, 402 (2012).
- 1173 36. Watson, A.J. Diffuse intra-sinusoidal metastatic carcinoma of the liver. *J Pathol*
1174 *Bacteriol* **69**, 207-17 (1955).
- 1175 37. Vaideeswar, P., Munot, S., Rojekar, A. & Deodhar, K. Hepatic diffuse intra-sinusoidal
1176 metastases of pulmonary small-cell carcinoma. *J Postgrad Med* **58**, 230-1 (2012).
- 1177 38. Stessels, F., Van den Eynden, G., Van der Auwera, I., Salgado, R., Van den Heuvel, E.,
1178 Harris, A.L. et al. Breast adenocarcinoma liver metastases, in contrast to colorectal
1179 cancer liver metastases, display a non-angiogenic growth pattern that preserves the
1180 stroma and lacks hypoxia. *Br J Cancer* **90**, 1429-36 (2004).
- 1181 39. Hoppener, D.J., Nierop, P.M.H., Herpel, E., Rahbari, N.N., Doukas, M., Vermeulen, P.B.
1182 et al. Histopathological growth patterns of colorectal liver metastasis exhibit little
1183 heterogeneity and can be determined with a high diagnostic accuracy. *Clin Exp*
1184 *Metastasis* **36**, 311-319 (2019).
- 1185 40. Terayama, N., Terada, T. & Nakanuma, Y. Histologic growth patterns of metastatic
1186 carcinomas of the liver. *Jpn J Clin Oncol* **26**, 24-9 (1996).
- 1187 41. Frentzas, S., Simoneau, E., Bridgeman, V.L., Vermeulen, P.B., Foo, S., Kostaras, E. et al.
1188 Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
1189 *Nat Med* **22**, 1294-1302 (2016).
- 1190 42. Bohlok, A., Vermeulen, P., Leduc, S., Latacz, E., Botzenhart, L., Richard, F. et al.
1191 Association between the histopathological growth patterns of liver metastases and
1192 survival after hepatic surgery in breast cancer patients. *NPJ Breast Cancer* **6**, 64 (2020).
- 1193 43. Horn, S.R., Stoltzfus, K.C., Lehrer, E.J., Dawson, L.A., Tchelebi, L., Gusani, N.J. et al.
1194 Epidemiology of liver metastases. *Cancer Epidemiol* **67**, 101760 (2020).
- 1195 44. Barnhill, R., Vermeulen, P., Daelemans, S., van Dam, P.J., Roman-Roman, S., Servois, V.
1196 et al. Replacement and desmoplastic histopathological growth patterns: A pilot study
1197 of prediction of outcome in patients with uveal melanoma liver metastases. *J Pathol*
1198 *Clin Res* **4**, 227-240 (2018).
- 1199 45. Barnhill, R., van Dam, P.J., Vermeulen, P., Champenois, G., Nicolas, A., Rawson, R.V. et
1200 al. Replacement and desmoplastic histopathological growth patterns in cutaneous
1201 melanoma liver metastases: frequency, characteristics, and robust prognostic value. *J*
1202 *Pathol Clin Res* **6**, 195-206 (2020).

- 1203 46. Grossniklaus, H.E., Zhang, Q., You, S., McCarthy, C., Heegaard, S. & Coupland, S.E.
1204 Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth
1205 patterns. *Hum Pathol* **57**, 165-175 (2016).
- 1206 47. Grossniklaus, H.E. Progression of ocular melanoma metastasis to the liver: the 2012
1207 Zimmerman lecture. *JAMA Ophthalmol* **131**, 462-9 (2013).
- 1208 48. Meyer, Y., Bohlok, A., Hoppener, D., Galjart, B., Doukas, M., Grunhagen, D.J. et al.
1209 Histopathological growth patterns of resected non-colorectal, non-neuroendocrine
1210 liver metastases: a retrospective multicenter study. *Clin Exp Metastasis* (2022).
- 1211 49. Fernandez Moro, C., Bozoky, B. & Gerling, M. Growth patterns of colorectal cancer
1212 liver metastases and their impact on prognosis: a systematic review. *BMJ Open*
1213 *Gastroenterol* **5**, e000217 (2018).
- 1214 50. Kwapisz, D. Oligometastatic breast cancer. *Breast Cancer* **26**, 138-146 (2019).
- 1215 51. Tran, C.G., Sherman, S.K., Chandrasekharan, C. & Howe, J.R. Surgical Management of
1216 Neuroendocrine Tumor Liver Metastases. *Surg Oncol Clin N Am* **30**, 39-55 (2021).
- 1217 52. Teng, S., Li, Y.E., Yang, M., Qi, R., Huang, Y., Wang, Q. et al. Tissue-specific transcription
1218 reprogramming promotes liver metastasis of colorectal cancer. *Cell Res* **30**, 34-49
1219 (2020).
- 1220 53. Nielsen, K., Rolff, H.C., Eefsen, R.L. & Vainer, B. The morphological growth patterns of
1221 colorectal liver metastases are prognostic for overall survival. *Mod Pathol* **27**, 1641-8
1222 (2014).
- 1223 54. Eefsen, R.L., Vermeulen, P.B., Christensen, I.J., Laerum, O.D., Mogensen, M.B., Rolff,
1224 H.C. et al. Growth pattern of colorectal liver metastasis as a marker of recurrence risk.
1225 *Clin Exp Metastasis* **32**, 369-81 (2015).
- 1226 55. Kuczynski, E.A., Yin, M., Bar-Zion, A., Lee, C.R., Butz, H., Man, S. et al. Co-option of Liver
1227 Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in
1228 Hepatocellular Carcinoma. *J Natl Cancer Inst* **108**, (2016).
- 1229 56. Bridgeman, V.L., Vermeulen, P.B., Foo, S., Bilecz, A., Daley, F., Kostaras, E. et al. Vessel
1230 co-option is common in human lung metastases and mediates resistance to anti-
1231 angiogenic therapy in preclinical lung metastasis models. *J Pathol* **241**, 362-374 (2017).
- 1232 57. Leenders, W.P., Kusters, B., Verrijp, K., Maass, C., Wesseling, P., Heerschap, A. et al.
1233 Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor
1234 progression via vessel co-option. *Clin Cancer Res* **10**, 6222-30 (2004).
- 1235 58. Martens, T., Laabs, Y., Gunther, H.S., Kemming, D., Zhu, Z., Witte, L. et al. Inhibition of
1236 glioblastoma growth in a highly invasive nude mouse model can be achieved by
1237 targeting epidermal growth factor receptor but not vascular endothelial growth factor
1238 receptor-2. *Clin Cancer Res* **14**, 5447-58 (2008).
- 1239 59. Mentha, G., Terraz, S., Morel, P., Andres, A., Giostra, E., Roth, A. et al. Dangerous halo
1240 after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver
1241 metastases. *Br J Surg* **96**, 95-103 (2009).
- 1242 60. Rubbia-Brandt, L., Giostra, E., Brezault, C., Roth, A.D., Andres, A., Audard, V. et al.
1243 Importance of histological tumor response assessment in predicting the outcome in
1244 patients with colorectal liver metastases treated with neo-adjuvant chemotherapy
1245 followed by liver surgery. *Ann Oncol* **18**, 299-304 (2007).
- 1246 61. Nierop, P.M., Hoppener, D.J., Buisman, F.E., van der Stok, E.P., Galjart, B.,
1247 Balachandran, V.P. et al. Preoperative systemic chemotherapy alters the
1248 histopathological growth patterns of colorectal liver metastases. *J Pathol Clin Res* **8**,
1249 48-64 (2022).

- 1250 62. Gomez Dorronsoro, M.L., Vera, R., Ortega, L., Plaza, C., Miquel, R., Garcia, M. et al.
1251 Recommendations of a group of experts for the pathological assessment of tumour
1252 regression of liver metastases of colorectal cancer and damage of non-tumour liver
1253 tissue after neoadjuvant therapy. *Clin Transl Oncol* **16**, 234-42 (2014).
- 1254 63. Powley, I.R., Patel, M., Miles, G., Pringle, H., Howells, L., Thomas, A. et al. Patient-
1255 derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and
1256 biomarker discovery. *Br J Cancer* **122**, 735-744 (2020).
- 1257 64. Voabil, P., de Bruijn, M., Roelofsen, L.M., Hendriks, S.H., Brokamp, S., van den Braber,
1258 M. et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in
1259 cancer. *Nat Med* **27**, 1250-1261 (2021).
- 1260 65. Fornabaio, G., Barnhill, R.L., Lugassy, C., Bentolila, L.A., Cassoux, N., Roman-Roman, S.
1261 et al. Angiotropism and extravascular migratory metastasis in cutaneous and uveal
1262 melanoma progression in a zebrafish model. *Sci Rep* **8**, 10448 (2018).
- 1263 66. Latacz, E., van Dam, P.J., Vanhove, C., Llado, L., Descamps, B., Ruiz, N. et al. Can medical
1264 imaging identify the histopathological growth patterns of liver metastases? *Semin*
1265 *Cancer Biol* **71**, 33-41 (2021).
- 1266 67. Wei, S., Han, Y., Zeng, H., Ye, S., Cheng, J., Chai, F. et al. Radiomics diagnosed
1267 histopathological growth pattern in prediction of response and 1-year progression free
1268 survival for colorectal liver metastases patients treated with bevacizumab containing
1269 chemotherapy. *Eur J Radiol* **142**, 109863 (2021).
- 1270 68. Er, E.E., Valiente, M., Ganesh, K., Zou, Y., Agrawal, S., Hu, J. et al. Pericyte-like spreading
1271 by disseminated cancer cells activates YAP and MRTF for metastatic colonization. *Nat*
1272 *Cell Biol* **20**, 966-978 (2018).
- 1273 69. Suzuki, K., Tanaka, M., Watanabe, N., Saito, S., Nonaka, H. & Miyajima, A. p75
1274 Neurotrophin receptor is a marker for precursors of stellate cells and portal fibroblasts
1275 in mouse fetal liver. *Gastroenterology* **135**, 270-281 e3 (2008).
- 1276 70. Wells, R.G. The portal fibroblast: not just a poor man's stellate cell. *Gastroenterology*
1277 **147**, 41-7 (2014).
- 1278 71. Trim, N., Morgan, S., Evans, M., Issa, R., Fine, D., Afford, S. et al. Hepatic stellate cells
1279 express the low affinity nerve growth factor receptor p75 and undergo apoptosis in
1280 response to nerve growth factor stimulation. *Am J Pathol* **156**, 1235-43 (2000).
- 1281 72. Passino, M.A., Adams, R.A., Sikorski, S.L. & Akassoglou, K. Regulation of hepatic stellate
1282 cell differentiation by the neurotrophin receptor p75NTR. *Science* **315**, 1853-6 (2007).
- 1283 73. Kendall, T.J., Henedige, S., Aucott, R.L., Hartland, S.N., Vernon, M.A., Benyon, R.C. et
1284 al. p75 Neurotrophin receptor signaling regulates hepatic myofibroblast proliferation
1285 and apoptosis in recovery from rodent liver fibrosis. *Hepatology* **49**, 901-10 (2009).
- 1286 74. Aimaiti, Y., Jin, X., Shao, Y., Wang, W. & Li, D. Hepatic stellate cells regulate hepatic
1287 progenitor cells differentiation via the TGF-beta1/Jagged1 signaling axis. *J Cell Physiol*
1288 **234**, 9283-9296 (2019).
- 1289 75. Cassiman, D., Deneef, C., Desmet, V.J. & Roskams, T. Human and rat hepatic stellate
1290 cells express neurotrophins and neurotrophin receptors. *Hepatology* **33**, 148-58
1291 (2001).
- 1292 76. Vidal-Vanaclocha, F., Crende, O., Garcia de Durango, C., Herreros-Pomares, A., Lopez-
1293 Domenech, S., Gonzalez, A. et al. Liver prometastatic reaction: Stimulating factors and
1294 responsive cancer phenotypes. *Semin Cancer Biol* **71**, 122-133 (2021).

- 1295 77. Ciner, A.T., Jones, K., Muschel, R.J. & Brodt, P. The unique immune microenvironment
1296 of liver metastases: Challenges and opportunities. *Semin Cancer Biol* **71**, 143-156
1297 (2021).
- 1298 78. Kurebayashi, Y., Kubota, N. & Sakamoto, M. Immune microenvironment of
1299 hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of
1300 colorectal adenocarcinoma: Relationship with histopathological and molecular
1301 classifications. *Hepatol Res* **51**, 5-18 (2021).
- 1302 79. Bohlok, A., Duran Derijckere, I., Azema, H., Lucidi, V., Vankerckhove, S., Hendlitz, A. et
1303 al. Clinico-metabolic characterization improves the prognostic value of histological
1304 growth patterns in patients undergoing surgery for colorectal liver metastases. *J Surg
1305 Oncol* **123**, 1773-1783 (2021).
- 1306 80. Matsumoto, K., Yoshitomi, H., Rossant, J. & Zaret, K.S. Liver organogenesis promoted
1307 by endothelial cells prior to vascular function. *Science* **294**, 559-63 (2001).
- 1308 81. Crivellato, E., Nico, B. & Ribatti, D. Contribution of endothelial cells to organogenesis:
1309 a modern reappraisal of an old Aristotelian concept. *J Anat* **211**, 415-27 (2007).
- 1310 82. Ding, B.S., Cao, Z., Lis, R., Nolan, D.J., Guo, P., Simons, M. et al. Divergent angiocrine
1311 signals from vascular niche balance liver regeneration and fibrosis. *Nature* **505**, 97-
1312 102 (2014).
- 1313 83. Daniel, E. & Cleaver, O. Vascularizing organogenesis: Lessons from developmental
1314 biology and implications for regenerative medicine. *Curr Top Dev Biol* **132**, 177-220
1315 (2019).
- 1316 84. Muthuswamy, S.K. Self-organization in cancer: Implications for histopathology, cancer
1317 cell biology, and metastasis. *Cancer Cell* **39**, 443-446 (2021).
- 1318 85. Pezzella, F., Di Bacco, A., Andreola, S., Nicholson, A.G., Pastorino, U. & Harris, A.L.
1319 Angiogenesis in primary lung cancer and lung secondaries. *Eur J Cancer* **32A**, 2494-500
1320 (1996).
- 1321 86. Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Breast Cancer
1322 Progression Working Party. *Lancet* **355**, 1787-8 (2000).
- 1323 87. Teuwen, L.A., De Rooij, L., Cuypers, A., Rohlenova, K., Dumas, S.J., Garcia-Caballero, M.
1324 et al. Tumor vessel co-option probed by single-cell analysis. *Cell Rep* **35**, 109253
1325 (2021).
- 1326 88. Lee, J.C., Green, M.D., Huppert, L.A., Chow, C., Pierce, R.H. & Daud, A.I. The Liver-
1327 Immunity Nexus and Cancer Immunotherapy. *Clin Cancer Res* **28**, 5-12 (2022).
- 1328 89. Garcia-Vicién, G., Mezheyeuski, A., Micke, P., Ruiz, N., Ruffinelli, J.C., Mills, K. et al.
1329 Spatial Immunology in Liver Metastases from Colorectal Carcinoma according to the
1330 Histologic Growth Pattern. *Cancers* **14**, 689 (2022).
- 1331 90. Szczepanski, J.M., Mendiratta-Lala, M., Fang, J.M., Choi, W.T., Karamchandani, D.M. &
1332 Westerhoff, M. Sinusoidal Growth Pattern of Hepatic Melanoma Metastasis:
1333 Implications for Histopathologic Diagnosis. *Am J Surg Pathol* (2021).
- 1334 91. Li, W.H., Wang, S., Liu, Y., Wang, X.F., Wang, Y.F. & Chai, R.M. Differentiation of
1335 histopathological growth patterns of colorectal liver metastases by MRI features.
1336 *Quant Imaging Med Surg* **12**, 608-617 (2022).
- 1337 92. de Ridder, J.A., Knijn, N., Wiering, B., de Wilt, J.H. & Nagtegaal, I.D. Lymphatic Invasion
1338 is an Independent Adverse Prognostic Factor in Patients with Colorectal Liver
1339 Metastasis. *Ann Surg Oncol* **22 Suppl 3**, S638-45 (2015).

- 1340 93. Serrablo, A., Paliogiannis, P., Pulighe, F., Moro, S.S., Borrego-Estella, V., Attene, F. et
1341 al. Impact of novel histopathological factors on the outcomes of liver surgery for
1342 colorectal cancer metastases. *Eur J Surg Oncol* **42**, 1268-77 (2016).
- 1343 94. Fonseca, G.M., de Mello, E.S., Faraj, S.F., Kruger, J.A.P., Coelho, F.F., Jeismann, V.B. et
1344 al. Prognostic significance of poorly differentiated clusters and tumor budding in
1345 colorectal liver metastases. *J Surg Oncol* **117**, 1364-1375 (2018).
- 1346 95. Cremolini, C., Milione, M., Marmorino, F., Morano, F., Zucchelli, G., Mennitto, A. et al.
1347 Differential histopathologic parameters in colorectal cancer liver metastases resected
1348 after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective
1349 trials. *Br J Cancer* **118**, 955-965 (2018).
- 1350 96. Falcao, D., Alexandrino, H., Caetano Oliveira, R., Martins, J., Ferreira, L., Martins, R. et
1351 al. Histopathologic patterns as markers of prognosis in patients undergoing
1352 hepatectomy for colorectal cancer liver metastases - Pushing growth as an
1353 independent risk factor for decreased survival. *Eur J Surg Oncol* **44**, 1212-1219 (2018).
- 1354 97. Ao, T., Kajiwara, Y., Yonemura, K., Shinto, E., Mochizuki, S., Okamoto, K. et al.
1355 Prognostic significance of histological categorization of desmoplastic reaction in
1356 colorectal liver metastases. *Virchows Arch* **475**, 341-348 (2019).
- 1357 98. Zhang, Y., Luo, X., Lin, J., Fu, S., Feng, P., Su, H. et al. Gelsolin Promotes Cancer
1358 Progression by Regulating Epithelial-Mesenchymal Transition in Hepatocellular
1359 Carcinoma and Correlates with a Poor Prognosis. *J Oncol* **2020**, 1980368 (2020).
- 1360 99. Baldin, P., Van den Eynde, M., Mlecnik, B., Bindea, G., Beniuga, G., Carrasco, J. et al.
1361 Prognostic assessment of resected colorectal liver metastases integrating pathological
1362 features, RAS mutation and Immunoscore. *J Pathol Clin Res* **7**, 27-41 (2021).
- 1363 100. Temido, M.J., Caetano Oliveira, R., Martins, R., Serodio, M., Costa, B., Carvalho, C. et
1364 al. Prognostic Factors After Hepatectomy for Gastric Adenocarcinoma Liver
1365 Metastases: Desmoplastic Growth Pattern as the Key to Improved Overall Survival.
1366 *Cancer Manag Res* **12**, 11689-11699 (2020).
- 1367 101. Jayme, V.R., Fonseca, G.M., Amaral, I.M.A., Coelho, F.F., Kruger, J.A.P., Jeismann, V.B.
1368 et al. Infiltrative Tumor Borders in Colorectal Liver Metastasis: Should We Enlarge
1369 Margin Size? *Ann Surg Oncol* **28**, 7636-7646 (2021).
- 1370 102. Zhang, Y.L., He, H.J., Cheng, J. & Shen, D.H. [Value of histopathological growth pattern
1371 in predicting 3-year progression free survival after operation in patients with liver
1372 metastasis of colorectal cancer]. *Zhonghua Bing Li Xue Za Zhi* **50**, 26-31 (2021).
- 1373 103. Meyer, Y.M., Beumer, B.R., Hoppener, D.J., Nierop, P.M.H., Doukas, M., de Wilde, R.F.
1374 et al. Histopathological growth patterns modify the prognostic impact of microvascular
1375 invasion in non-cirrhotic hepatocellular carcinoma. *HPB (Oxford)* (2021).
- 1376 104. Vles, M.D., Hoppener, D.J., Galjart, B., Moelker, A., Vermeulen, P.B., Grunhagen, D.J.
1377 et al. Local tumour control after radiofrequency or microwave ablation for colorectal
1378 liver metastases in relation to histopathological growth patterns. *HPB (Oxford)* (2022).
- 1379 105. Ceausu, A.R., Ciolofan, A., Cimpean, A.M., Magheti, A., Mederle, O. & Raica, M. The
1380 Mesenchymal-Epithelial and Epithelial-Mesenchymal Cellular Plasticity of Liver
1381 Metastases with Digestive Origin. *Anticancer Res* **38**, 811-816 (2018).
- 1382 106. Lazaris, A., Amri, A., Petrillo, S.K., Zoroquiain, P., Ibrahim, N., Salman, A. et al.
1383 Vascularization of colorectal carcinoma liver metastasis: insight into stratification of
1384 patients for anti-angiogenic therapies. *J Pathol Clin Res* **4**, 184-192 (2018).
- 1385 107. Wu, J.B., Sarmiento, A.L., Fiset, P.O., Lazaris, A., Metrakos, P., Petrillo, S. et al.
1386 Histologic features and genomic alterations of primary colorectal adenocarcinoma

- 1387 predict growth patterns of liver metastasis. *World J Gastroenterol* **25**, 3408-3425
1388 (2019).
- 1389 108. Blank, A., Schenker, C., Dawson, H., Beldi, G., Zlobec, I. & Lugli, A. Evaluation of Tumor
1390 Budding in Primary Colorectal Cancer and Corresponding Liver Metastases Based on
1391 H&E and Pancytokeratin Staining. *Front Med (Lausanne)* **6**, 247 (2019).
- 1392 109. Palmieri, V., Lazaris, A., Mayer, T.Z., Petrillo, S.K., Alamri, H., Rada, M. et al. Neutrophils
1393 expressing lysyl oxidase-like 4 protein are present in colorectal cancer liver metastases
1394 resistant to anti-angiogenic therapy. *J Pathol* **251**, 213-223 (2020).
- 1395 110. Ao, T., Kajiwarra, Y., Yonemura, K., Shinto, E., Mochizuki, S., Okamoto, K. et al.
1396 Morphological consistency of desmoplastic reactions between the primary colorectal
1397 cancer lesion and associated metastatic lesions. *Virchows Arch* **477**, 47-55 (2020).
- 1398 111. Rada, M., Kapelanski-Lamoureux, A., Petrillo, S., Tabaries, S., Siegel, P., Reynolds, A.R.
1399 et al. Runt related transcription factor-1 plays a central role in vessel co-option of
1400 colorectal cancer liver metastases. *Commun Biol* **4**, 950 (2021).
- 1401 112. Burren, S., Reche, K., Blank, A., Galvan, J.A., Dawson, H., Berger, M.D. et al. RHAMM in
1402 liver metastases of stage IV colorectal cancer with mismatch-repair proficient status
1403 correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1. *Pathol Res Pract* **223**,
1404 153486 (2021).
- 1405 113. Donnem, T., Reynolds, A.R., Kuczynski, E.A., Gatter, K., Vermeulen, P.B., Kerbel, R.S. et
1406 al. Non-angiogenic tumours and their influence on cancer biology. *Nat Rev Cancer* **18**,
1407 323-336 (2018).
- 1408 114. Baldin, P., Van den Eynde, M., Hubert, C., Jouret-Mourin, A. & Komuta, M. The role of
1409 the pathologist and clinical implications in colorectal liver metastasis. *Acta*
1410 *Gastroenterol Belg* **81**, 419-426 (2018).
- 1411 115. Kuczynski, E.A., Vermeulen, P.B., Pezzella, F., Kerbel, R.S. & Reynolds, A.R. Vessel co-
1412 option in cancer. *Nat Rev Clin Oncol* **16**, 469-493 (2019).
- 1413 116. Oliveira, R.C., Alexandrino, H., Cipriano, M.A. & Tralhao, J.G. Liver Metastases and
1414 Histological Growth Patterns: Biological Behavior and Potential Clinical Implications-
1415 Another Path to Individualized Medicine? *J Oncol* **2019**, 6280347 (2019).
- 1416 117. Kuczynski, E.A. & Reynolds, A.R. Vessel co-option and resistance to anti-angiogenic
1417 therapy. *Angiogenesis* **23**, 55-74 (2020).
- 1418 118. Oliveira, R.C., Alexandrino, H., Cipriano, M.A., Alves, F.C. & Tralhao, J.G. Predicting liver
1419 metastases growth patterns: Current status and future possibilities. *Semin Cancer Biol*
1420 **71**, 42-51 (2021).
- 1421 119. Rigamonti, A., Feuerhake, F., Donadon, M., Locati, M. & Marchesi, F. Histopathological
1422 and Immune Prognostic Factors in Colo-Rectal Liver Metastases. *Cancers (Basel)* **13**,
1423 (2021).
- 1424 120. Garcia-Vicien, G., Mezheyeuski, A., Banuls, M., Ruiz-Roig, N. & Mollevi, D.G. The Tumor
1425 Microenvironment in Liver Metastases from Colorectal Carcinoma in the Context of
1426 the Histologic Growth Patterns. *Int J Mol Sci* **22**, (2021).
- 1427 121. Haas, G., Fan, S., Ghadimi, M., De Oliveira, T. & Conradi, L.C. Different Forms of Tumor
1428 Vascularization and Their Clinical Implications Focusing on Vessel Co-option in
1429 Colorectal Cancer Liver Metastases. *Front Cell Dev Biol* **9**, 612774 (2021).
- 1430 122. Rompianesi, G., Pegoraro, F., Ceresa, C.D., Montalti, R. & Troisi, R.I. Artificial
1431 intelligence in the diagnosis and management of colorectal cancer liver metastases.
1432 *World J Gastroenterol* **28**, 108-122 (2022).

- 1433 123. Paku, S. & Lapis, K. Morphological aspects of angiogenesis in experimental liver
1434 metastases. *Am J Pathol* **143**, 926-36 (1993).
- 1435 124. Vidal-Vanaclocha, F. The prometastatic microenvironment of the liver. *Cancer*
1436 *Microenviron* **1**, 113-29 (2008).
- 1437 125. Barsky, S.H., Doberneck, S.A., Sternlicht, M.D., Grossman, D.A. & Love, S.M. 'Revertant'
1438 DCIS in human axillary breast carcinoma metastases. *J Pathol* **183**, 188-94 (1997).
- 1439 126. Schuppan, D. & Kim, Y.O. Evolving therapies for liver fibrosis. *J Clin Invest* **123**, 1887-
1440 901 (2013).
- 1441 127. Dezso, K., Papp, V., Bugyik, E., Hegyesi, H., Safrany, G., Bodor, C. et al. Structural
1442 analysis of oval-cell-mediated liver regeneration in rats. *Hepatology* **56**, 1457-67
1443 (2012).
- 1444

Table 1.

First author	Reference	Methodology	Tumour type	Main findings
<i>Animal models</i>				
Alzubi M.A.	Clin Exp Metastasis 2019 ¹¹	Portal vein injection of cancer cells of PDX mammary tumours of 14 patients in NOD <i>scid gamma</i> mice.	Breast cancer	HGPs could be assessed in six PDX models: replacement, desmoplastic and pushing HGPs were identified.
Piquet L.	Cancers 2019 ¹²	Co-inoculation into the spleen of human primary hepatic stellate cells and 5 human uveal melanoma cell lines in NOD <i>scid gamma</i> or NOD CRISPR <i>Prkdc Il2r gamma</i> mice.	Uveal Melanoma	Desmoplastic, replacement and mixed liver metastases were observed. The HGP was not altered by co-inoculation of stellate cells (figure 5A and table 2 of the publication)
Vlachogiannis G.	Science 2018 ¹³	A biobank of patient-derived organoids and xenografts was constructed (110 fresh biopsies from 71 patients enrolled in four prospective phase 1/2 clinical trials were processed)	Colorectal and gastro-oesophageal cancer	A predominance of replacement HGP was observed in xenografts from resistant patient, whereas tumours established from sensitive patient showed a prevalence of desmoplastic and pushing HGPs.
Ibrahim N.S.	Cancers 2020 ¹⁴	Intra-splenic injection of MC-38 mouse CRC cell line in inducible Ang1 knock-out C57BL/6 mice.	Colorectal cancer	Replacement HGP liver metastases in control mice and desmoplastic HGP liver metastases in Ang1 knock-out condition.

Masaki S.	Int J Exp Pathol 2020 ¹⁵	Fatty liver conditions were induced in BALB/c mice. CT26 cells were injected into the liver.	Colorectal cancer	Tumours in control mice showed encapsulated growth patterns, while tumours in fatty livers showed invasive growth without encapsulation.
Tabariès S.	Commun Biol 2021 ¹⁶	Intrahepatic transplantation of patient liver metastasis tissue fragments in Scid-beige mice. Expression profiles of claudins were compared between dHGP and rHGP in PDXs and in liver metastases of patients.	Colorectal cancer	Liver metastases in mice express the HGP of the liver metastases of the patient-donor. Claudin-2 in patient-derived extracellular vesicles may be a marker of rHGP.
Bartlett A.	Cancers 2021 ¹⁷	Portal vein injection of D2OR, a low metastatic mouse mammary tumour cell line in nulliparous BALB/c immune competent mice and weaning-induced liver involution mice.	Breast cancer	The post-weaning liver is in an immune suppressed state with increased tumour incidence and multiplicity. A greater diversity of HGPs was noted in the post-weaning mice, consistent with the liver microenvironment dictating tumour histology.
Immune contexture (also: Watanabe K. in 'HGP scoring methodology' section)				
Stremitzer S.	Br J Cancer 2020 ²	The immune phenotype of liver metastases was scored based on the distribution of CD8-immunostained cytotoxic T-lymphocytes as 'desert', 'excluded' (together 'non-inflamed') and 'inflamed' (81 patients). Bevacizumab-based chemotherapy was administered to all patients before partial liver resection.	Colorectal cancer	The inflamed immune phenotype was associated with the desmoplastic HGP and was associated with improved RFS and OS in univariable, not multivariable analyses.

Liang J.	Cancer Immunol Immunother 2020 ³	The immunoscore was calculated according to the densities of immunostained CD3 + and CD8 + cells (166 patients). One immunoscore per patient was calculated based on assessments in the tumour centre and in the invasive margin.	Colorectal cancer	A high immunoscore was more often encountered in liver metastases with a desmoplastic HGP than with a replacement HGP. A combined risk score (HGP, immunoscore and clinical risk score) was developed and a 90% 5-year OS rate was observed for patients in the low-risk group (30% of the patients).
Höppener D.J.	Br J Cancer 2020 ⁴	The immune contexture of resected liver metastases was analysed in 3 cohort of chemo-naive patients (117, 34 and 79 patients, respectively) with immunohistochemistry (semi-quantitative grading, quantitative digital image analysis) and flow cytometry. The 100% desmoplastic HGP cut off was applied.	Colorectal cancer	An increased immune infiltrate is associated with the desmoplastic HGP, both surrounding and in the metastases. Intra-epithelial CD8+ cells were also increased in the desmoplastic HGP.
Messaoudi N.	Br J Cancer. 2022 ⁶	Immunohistochemistry and automated quantitative analysis on tissue microarray (176 patients) of CD3, MHC-I and CD73. Liver metastases were categorized according to the dominant HGP and according to the 100% desmoplastic HGP cut off.	Colorectal cancer	Desmoplastic liver metastases were more infiltrated by CD3 + cells, expressed lower levels of MHC-I, and similar levels of CD73. Elevated CD73 expression was associated with a worse outcome of patients with desmoplastic HGP liver metastases. Low MHC-I expression in patients with

				replacement-type metastases improved outcome.
Garcia-Vicién G	Cancers 2022 ⁸⁹	The spatial distribution of lymphocytic infiltrates in CRC liver metastases was explored in the context of the HGPs by multiplex immunofluorescence staining and digital image analysis in a cohort of 22 resected metastases without pre-surgery chemotherapy. HGPs were scored following the previous guidelines. The desmoplastic rim was excluded from the invasive margin for lymphocyte counting ('Measure B').	Colorectal cancer	The number of CD8-positive cells at the invasive margin was independent of the HGP. In non-desmoplastic metastases, the cytotoxic T cells did not enter the tumour cell nests and CD4-positive cells were more abundant at the invasive margin than in desmoplastic lesions.
<i>HGP scoring methodology</i>				
Höppener D.J.	Clin Exp Metastasis 2019 ³⁹	Within and between metastasis HGP concordance was analysed in 363 patients with 2 or more resected liver metastases. The association of diagnostic accuracy with number of sections and number of metastases evaluated was determined. Interobserver agreement of HGP scoring was assessed after training. The 100% desmoplastic HGP cut off was applied.	Colorectal cancer	Within metastasis concordance ranged from 93% to 96%. Between metastasis concordance was 90%. Diagnostic accuracy peaked at two sections and two metastases. After two training sessions, interobserver agreement had a kappa-value of more than 0.9.
Watanabe K.	Cancer Med 2020 ⁵	Biopsies of liver metastases of 107 patients with pancreatic cancer (21- or 18-gauge needle) were used for HGP assessment. The dominant HGP was determined. If a HGP was present in more than	Pancreatic cancer	Of 279 patients, 107 patients had a biopsy that contained the tumour-liver interface. HGP had a homogenous expression in 13/14 patients. Disease control

		80% of the interface, the HGP was called 'homogenous' (analysis in 14 patients).		rate as well as overall survival rate were lower in the replacement HGP group. The replacement HGP biopsies showed less inflammation (H&E) and contained less CD8 + cells than the other biopsies.
Szczepanski J.	Am J Surg Pathol 2021 ⁹⁰	The HGP was scored in biopsies of liver metastases of melanoma (n=30; 22 skin melanomas; 6 ocular melanomas; 2 unknown origin).	Melanoma	In 8/30 (4 ocular, 4 skin, 27%) melanoma liver metastases, a sinusoidal HGP was seen. In none of the 96 metastases of breast, colon, pancreaticobiliary cancer and neuroendocrine tumours this HGP was encountered.
Medical imaging				
Gulia S.	BMJ Case Rep 2016 ⁷	A case report of a radiographically occult liver metastasis leading to liver failure is presented.	Breast cancer	A biopsy established the diagnosis of a liver metastasis with intra-sinusoidal growth pattern.
Cheng J.	Ann Surg Oncol 2019 ⁸	A radiomic algorithm was developed to identify the dominant HGPs of liver metastases by computed tomography (CT) imaging. Pre- and post-contrast as well as arterial and portal venous phase images (ROI: tumour-liver interface) contributed to the algorithm (126 metastases of 94 chemo-naive patients - variety of scanners but standardized acquisition protocol and use of contrast agent).	Colorectal cancer	The dominant HGP of the liver metastases could be predicted with 65% sensitivity and 92% specificity (accuracy of 77%). A decisive feature used by the algorithm is the presence (desmoplastic) or absence (replacement) of peripheral rim enhancement in the portal-

				venous phase. No clinical or qualitative image data were used by the algorithm.
Han Y.	Front Oncol 2020 ⁹	A radiomic algorithm was developed to identify the dominant HGP of liver metastases by magnetic resonance imaging (MRI). (ROI: tumour-liver interface (TLI) - 182 liver metastases (107 chemo-naive patients))	Colorectal cancer	The radiomic algorithm that best predicted the dominant HGP was based on quantitative features extracted from the TLI combined with clinical data and a qualitative image feature ('lobular margin') (79% accuracy, 100% sensitivity, 35% specificity). The desmoplastic HGP had more heterogeneous radiomic features than the replacement HGP.
Starmans M.P.A.	Clin Exp Metastasis 2021 ¹⁰	A radiomic algorithm was developed to distinguish liver metastases with 100% desmoplastic HGP from liver metastases with 100% replacement HGP by CT imaging (76 chemo-naive patients with 93 metastases).	Colorectal cancer	Despite the use of only portal venous phase contrast-enhanced images, variations in lesion segmentation and acquisition protocols, accuracy was 65%, sensitivity 72% and specificity 58%.
Wei S.	Eur J Radiol 2021 ⁶⁷	The CT image-based radiomics algorithm to identify the dominant HGP developed in Cheng et al. (2019) was used to predict response to bevacizumab-chemotherapy in 119 patients (346 lesions) with unresectable CRC liver metastases.	Colorectal cancer	AUC for predicting early response was 0.72. The radiomics algorithm-derived HGP was the only independent predictor of 1-year PFS.

Li W.H.	Quant Imaging Med Surg 2022 ⁹¹	MRI features were used to predict the dominant HGP in 53 chemo-naïve patients.	Colorectal cancer	AUC for predicting the dominant HGP based on diameter difference between pre- and post-contrast images and rim enhancement was 0.83.
HGP as biomarker (HGP assessment <i>not according to guidelines</i> , <i>according to guidelines with dominant HGP as categories</i> and <i>according to guidelines with 100% desmoplastic HGP versus any percentage of replacement as categories</i>)				
de Ridder J.A.M.	Ann Surg Onc 2015 ⁹²	The presence/absence of a fibrous capsule was scored on H&E sections of resected liver metastases of 124 chemo-naïve patients with a solitary metastasis. The proportion of the tumour-liver interface with/without capsule was not reported.	Colorectal cancer	In univariable but not multivariable analysis, the presence of a fibrous capsule was associated with improved OS (109 months versus 57 months).
Serrablo A.	Eur J Surg Oncol 2016 ⁹³	The presence/absence of a fibrous capsule with a thickness of at least 0,5mm in the entire tumour-liver interface was assessed on H&E sections (147 patients: 74/147 with pre-surgery systemic treatment)	Colorectal cancer	The capsule was present in 17% of the patients, independent of pre-surgery treatment status, and did not have an impact on survival.
Fonseca G.M.	J Surg Oncol 2018 ⁹⁴	Tumour border pattern was scored according to the Jass classification (infiltrative, expansive). A fibrous capsule was scored as being absent or present. A single tissue block of the largest metastasis was selected for each patient (229 patients, all with peri-operative systemic treatment).	Colorectal cancer	Both absence of a fibrous capsule (75% of patients) and infiltrative growth (74% of patients) were associated with shorter OS and DFS in multivariable and/or univariable analyses. Both parameters were also associated with hepatic recurrence.

Cremolini C.	Br J Cancer 2018 ⁹⁵	HGPs were scored according to the international guidelines. The effect of the HGPs on OS and DFS was investigated in a cohort of patients with liver metastases and with chemotherapy combined with either bevacizumab or cetuximab prior to surgery (159 patients).	Colorectal cancer	There was no effect of HGP on OS or DFS. An important remark is that the proportion of patients with liver metastases with a dominant pushing HGP was much higher than reported in most other studies (41%).
Falcao D.	Eur J Surg Oncol 2018 ⁹⁶	HGPs of liver metastases were scored in 110 patients of which 52 patients received pre-surgery chemotherapy. A mixed HGP was identified when more than one HGP was expressed by the metastases and each HGP was present in at least 25% of the interface.	Colorectal cancer	The pushing HGP was independently associated with worse OS and DFS. An important remark is that the proportion of patients with liver metastases with a pushing HGP was much higher than reported in most other studies (30%).
Barnhill R.	J Pathol Clin Res 2018 ⁴⁴	The dominant HGP was scored according to the international guidelines. Gene alterations were assessed by array CGH (41 liver metastases originating from 41 patients).	Uveal melanoma	Dominant replacement HGP metastases were present in 73% of patients (27%: desmoplastic HGP). On multivariate analysis, only HGP and resection status predicted OS (HR of 6.5 for replacement HGP).
Galjart B.	Angiogenesis 2019 ¹⁸	HGPs were scored according to the international guidelines but patients were categorized as having 100% desmoplastic (dHGP) liver metastases or not (non-dHGP) (732 patients of which 367 chemo-naïve before surgery)	Colorectal cancer	About 20% of the patients with surgical resection of CRC liver metastases ended up in 100% dHGP group. This was associated with an outstanding outcome, especially in the chemo-naïve group (78% with at least 5 years OS)

Nierop P.M.H.	Clin Exp Metastasis 2019 ²³	HGP was scored as 100% desmoplastic (dHGP) versus non-dHGP in 690 patients free of disease after first resection of liver metastases of which 492 developed recurrent disease.	Colorectal cancer	Patients with dHGP at first partial hepatectomy were more often treated with curative intent and more often had recurrences salvageable by local treatment modalities.
Ao T	Virchows Arch 2019 ⁹⁷	The desmoplastic reaction in and around liver metastases was scored as mature/intermediate (mature collagen fibers and keloid-like collagen) and immature (myxoid collagen present) in 204 patients with resected liver metastases of which 78 had received preoperative chemotherapy	Colorectal cancer	The type of desmoplastic reaction was independently associated with outcome with 65% 5-years OS in the mature /intermediate group versus 35% in the immature group.
Barnhill R	J Pathol Clin Res 2020 ⁴⁵	HGP was scored as 100% desmoplastic (dHGP) versus 'any % of replacement' (any rHGP) (43 liver metastases from 42 patients).	Cutaneous melanoma	Multivariate analysis demonstrated that only HGP was associated with OS after resection of the liver metastases (HR for 'any rHGP' of 3.8).
Zhang Y	J Oncol 2020 ⁹⁸	Encapsulation of hepatocellular carcinoma was assessed in 188 patients (method not specified).	Hepatocellular carcinoma	In multivariate analyses, the presence of a capsule was associated with improved DFS and OS (HR of 0.60 and 0.51, respectively).
Buisman F.E.	Clin Exp Metastasis 2020 ²⁵	HGP was scored as 100% desmoplastic (dHGP) versus non-dHGP in resected liver metastases of 1236 patients of whom 656 received pre-operative chemotherapy.	Colorectal cancer	Adjuvant chemotherapy improved OS and DFS only in patients with non-dHGP liver metastases who did not receive pre-operative chemotherapy (HR of 0.52 and 0.71, respectively)

Baldin P.	J Pathol Clin Res 2021 ⁹⁹	A pathological score (combining 'more than 3 lesions', 'R1 positive margin', 'non-100% desmoplastic HGP', 'steatohepatitis') and the consensus Immunoscore were tested for effect on outcome in 221 patients (85% received pre-operative chemotherapy; 582 liver metastases). Remark: per patient HGP used for outcome analysis was determined by selecting the 'worst' metastasis: pure replacement or mixed HGP.	Colorectal cancer	Non-desmoplastic HGP predicted shorter time to relapse in univariate and multivariate analyses (HRs 1,84 en 1,75, respectively). Patients with a favourable pathological score and a high immunoscore had the lowest risk of relapse (about 60% 5 yrs survival).
Temido M.	Cancer Management and Research 2020 ¹⁰⁰	HGP was scored as dHGP (100%) versus any % of non-desmoplastic growth (17 patients).	Gastric cancer	dHGP was independently associated with improved OS (HR=0.1, p=0.02).
Bohlok A.	NPJ Breast Cancer 2020 ⁴²	HGP was scored as 100% replacement (rHGP) versus 'any % of desmoplastic (any dHGP) (36 patients (11 patients with multiple metastases)).	Breast cancer	Any dHGP was independently associated with better PFS after liver surgery when compared with rHGP (HR=0.24, p = 0.009). All patients with rHGP relapsed within 20 months after liver surgery.
Jayme V.R.	Ann Surg Oncol 2021 ¹⁰¹	Tumour growth pattern of CRC liver metastases was defined as 'infiltrative' or 'pushing', according to Jass J.R. in 182 patients who underwent partial hepatectomy.	Colorectal cancer	Patients with infiltrative liver metastases (68% of patients) had worse OS and DFS, independent of surgical margin width.
Zhang Y.L.	Zhonghua Bing Li Xue Za Zhi 2021 ¹⁰²	The dominant HGP was scored according to the international guidelines in 80 patients with partial hepatectomy.	Colorectal cancer	The 3-year PFS of patients with dHGP liver metastases (54%) was significantly longer compared with rHGP (40%).

				HGP was an independent prognostic factor for survival.
Höppener D.J.	JNCI Cancer Spectr 2021 ¹⁹	HGP was scored as dHGP (100%) versus any % of non-desmoplastic growth in international multicentre retrospective validation study (780 patients treated by liver surgery).	Colorectal cancer	The association of dHGP and good outcome was confirmed, independent of <i>KRAS</i> and <i>BRAF</i> status. The presence, not the extent, of a non-desmoplastic component, negatively impacts outcome.
Meyer J.M.	HPB (Oxford) 2021 ¹⁰³	In a cohort of 155 patients with resected non-cirrhotic hepatocellular carcinoma (HCC), HGP (100% desmoplastic versus any % of replacement) and microvascular invasion (MVI) were scored.	Hepatocellular carcinoma	Both non-dHGP and MVI were associated with worse outcome (OS, DFS) in multivariate analyses. For OS, there was effect modification between HGP and MVI, with patients with MVI and non-dHGP having the shortest survival time.
Vles M-J	HPB (Oxford) 2022 ¹⁰⁴	In a cohort of 221 patients who received simultaneous resection and ablation as a first treatment for liver metastases, HGP was scored in the resected metastases (100% desmoplastic versus any % of replacement (non-desmoplastic)).	Colorectal cancer	A non-desmoplastic HGP of the resected metastases independently predicted local tumour progression adjacent to the post-ablation zone (HR of 1.55 (p = 0.04)).
Meyer Y	Clin Exp Metastasis 2022 ⁴⁸	In a cohort of 132 patients with liver metastases from 25 different tumour types, HGP was scored (100% desmoplastic versus any % of replacement (non-desmoplastic)).	Non-colorectal, non-neuroendocrine tumours	The HGPs could be identified in all tumour types. A desmoplastic HGP was associated with favourable outcome (OS: HR of 0.51 (p =

				0.04); RFS: HR of 0.38 (p < 0.01)) upon multivariable analysis.
HGP and tumour biology				
Grossniklaus H.E.	Hum Pathol 2016 ⁴⁶	Post-mortem histological liver analysis of 15 patients who died from metastatic uveal melanoma. Immunofluorescence staining for MMP9 and VEGF.	Uveal melanoma	Cancer cells in the 'infiltrative' growth pattern (resembling replacement HGP) do not express VEGF and MMP9, while cancer cells in the 'nodular' growth pattern (resembling pushing & desmoplastic HGP) express VEGF and MMP9. Hypothesis: infiltrative metastases originate in the sinusoidal space while nodular metastases originate in the portal tracts.
Ceausu A.R.	Anticancer Res 2018 ¹⁰⁵	Double immunostaining for keratin8/18-vimentin and for E-cadherin-vimentin. The mesenchymal/epithelial hybrid phenotype cells were quantified (25 patients).	Colorectal, pancreatic and gastric cancer	All the liver metastases of pancreatic cancer had a replacement HGP; all the liver metastasis of gastric cancer had a pushing HGP; CRC liver metastases exhibited all 3 HGPs. Replacement and pushing type metastases have a higher amount of cancer cells with EMT phenotype than desmoplastic metastases.

Lazaris A.	J Pathol Clin Res 2018 ¹⁰⁶	Immunohistochemistry (CD31 and CD34/Ki67; VEGF) to quantify microvessel density and blood vessels with endothelial cell proliferation (50 liver metastases of 50 patients). The dominant HGP was determined.	Colorectal cancer	Metastases with a desmoplastic HGP have a lower microvessel density than metastases with a replacement HGP. Endothelial cell proliferation was much higher in desmoplastic liver metastases unless systemic treatment was given prior to surgery. In chemo-naïve patients, there was no difference in VEGF-expression levels between both HGPs.
Wu J.B.	World J Gastroenterol 2019 ¹⁰⁷	HGP was scored in the liver metastases and in the primary tumours (liver metastases from 29 patients with matching primary tumours). Additional histological parameters were assessed in the primary tumours. Whole exome sequencing (WES) was performed on 5 cases.	Colorectal cancer	15 cases with desmoplastic HGP and 14 cases with replacement HGP. High tumour budding score, absence of Crohn's disease-like inflammatory response and infiltrating HGP of the primary tumour were associated with replacement HGP. Small cohort with WES results.
Nierop P.M.H.	HPB Oxford 2019 ²⁴	All available H&E-stained sections of all resected CRC liver metastases from 1302 patients were used for HGP scoring (100% desmoplastic versus any% of replacement). Hepatic resection margins were evaluated as positive or negative.	Colorectal cancer	Upon multivariate analyses, a non-desmoplastic HGP and number of metastases was associated with increased risk of positive resection margins.

Blank A.	Front Med 2019 ¹⁰⁸	Tissue microarray of 81 primary tumours and 139 corresponding liver metastases. Tumour budding was scored in primary CRCs and in liver metastases (intra- and peri-metastatic) on H&E and pan-cytokeratin-stained section. The association of budding in the primary tumour and HGP of the liver metastases was not analysed.	Colorectal cancer	Assessment of budding only reliable in desmoplastic liver metastases without extensive ductular reaction. No clear association of budding in primary CRC and metastases.
Palmieri V.	J Pathol 2020 ¹⁰⁹	RNA sequencing (16 liver metastases from chemo-naive patients: 7 predominant replacement HGP and 9 desmoplastic) and immunohistochemistry (20 liver metastases from chemo-naive patients: 10 replacement and 10 desmoplastic cases).	Colorectal cancer	<i>CXCL6</i> and <i>LOXL4</i> upregulated in replacement HGP metastases. <i>LOXL4</i> protein is expressed in neutrophils at the tumour-liver interface of these metastases.
Ao T.	Virchows Archiv 2020 ¹¹⁰	The association of the type of desmoplastic reaction (mature, intermediate, immature) in the primary tumour and the liver metastases was investigated in 45 patients with synchronous liver metastases.	Colorectal cancer	A significant association was reported ($r=0.40$, $P = 0.0069$).
Bohlok A.	J Surg Oncol 2021 ⁷⁹	The metabolic Clinical Risk Score (mCRS), which includes FDG-PET as a metabolic parameter, was compared with the HGP of liver metastases and the prognostic value of combining mCRS and HGP was assessed in 108 patients.	Colorectal cancer	Liver metastases with a 100% desmoplastic HGP had a significantly lower glucose-uptake (metabolic activity) than non-desmoplastic liver metastases. A low mCRS was associated with improved outcome in patients with dHGP liver metastases.

Rada M.	Commun Biol 2021 ¹¹¹	Gene expression analyses and subsequent validation by immunohistochemistry in clinical samples of CRC liver metastases. Functional validation by targeted knock-down in CRC cancer cell lines and by using animal models.	Colorectal cancer	RUNX1 overexpression was shown to play a central in vessel co-option during replacement growth by inducing cancer cell motility and EMT. TSP1 and TGFbeta1 are involved in this process.
Burren S.	Pathol Res Pract 2021 ¹¹²	In a cohort of 76 patients with mismatch repair proficient CRC liver metastases, HGP and peripheral and central budding were scored.	Colorectal cancer	Liver metastases with a replacement HGP more often show budding in their centre than desmoplastic metastases.
Nierop P.M.H.	J Pathol Clin Res 2021 ⁶¹	In 3 cohorts of patients (n=877, 1203 and 70) the effect on pre-surgery chemotherapy on the HGP was assessed. The cohort of 70 patients belongs to a randomized clinical study.	Colorectal cancer	On average, the presence of a desmoplastic HGP increased with a factor of 1.5 when chemotherapy was administered before surgery. This was confirmed in the randomized study. The biology of the 'converted' metastases remains unclear.
<i>Review manuscripts</i>				
van Dam P-J.	Semin Cancer Biol 2018 ³²	Key differentiating histopathological characteristics of the HGPs and their impact on tumour biology are described. The review sums up arguments to support the hypothesis that the HGPs of liver metastasis have distinct cancer immune set-points and, thus, might affect clinical management strategies when immunomodulatory treatment is considered.		

Donnem T.	Nat Rev Cancer 2018 ¹¹³	The discovery of non-angiogenic, vessel co-opting tumour growth is described as well as the biology of this means of vascularization and the implications for cancer treatment. The replacement HGP of liver metastases is discussed as one of the examples of non-angiogenic growth described in human studies.
Fernández Moro C.	BMJ Open Gastro 2018 ⁴⁹	This review has identified all studies up to December 2017 that reported the HGPs in patients with liver metastatic CRC, the relative frequencies of these HGPs, and the association with outcome. In 14 out of 17 cohorts, a significant favourable outcome was reported for patients with desmoplastic liver metastases. In 8 out of 12 cohorts, a significantly unfavourable outcome for patients with replacement-type liver metastases was found. The authors found no studies that reported an opposite association between HGP and outcome.
Baldin P.	Acta Gastroenterol Belg 2018 ¹¹⁴	The review summarizes prognostic/predictive histopathological and molecular parameters for patients with liver metastatic colorectal cancer, the HGPs being one of these parameters. The authors argue for the integration of HGP in the pathology report.
Kuczynski E.A.	Nat Rev Clin Oncol 2019 ¹¹⁵	Evidence that tumours located in numerous organs can use vessel co-option as a mechanism of tumour vascularization is described, the liver with the replacement HGP of metastases being one of the highlighted organs. Molecular mechanisms and implications for patients are also discussed.
Caetano Oliveira R.	J Oncol 2019 ¹¹⁶	The prognostic significance, the biology and the therapeutic implications of the HGPs of CRC liver metastases are discussed. The authors propose to include the HGPs in the pathology report of resection of hepatic metastases.
Kuczynski E.A.	Angiogenesis 2020 ¹¹⁷	The authors collected evidence linking vessel co-option with resistance to anti-angiogenic drugs in numerous tumour types. In human studies of both primary hepatocellular carcinoma and liver metastases the non-angiogenic replacement growth pattern has been described. The authors list the studies in animals and humans that associate this growth pattern with resistance to anti-VEGF and/or anti-angiogenic compounds.

Latacz E.	Angiogenesis 2020 ³¹	The authors of this review hypothesize that common biological themes may be responsible for the HGPs of tumours in different organs, for example brain, lungs and liver. They further stress that cancer cell motility may be one of the driving forces behind the vessel co-opting (replacement) HGP.
Blazquez R.	Semin Cancer Biol 2020; 60: 324-333	Nine patterns of the macro-metastasis/organ parenchyma interface (MMPI) divided over 3 groups are described. The 3 subgroups are: 'displacing' (non-infiltrative) and two infiltrative MMPI-groups: 'epithelial' and 'diffuse'. An organ-independent MMPI assessment protocol is proposed.
Latacz E.	Semin Cancer Biol 2021 ⁶⁶	The authors argue that, based on the (retrospective) studies discussed in this review, we will be able to identify HGPs of liver metastases through medical imaging soon. This will significantly encourage medical oncologists to implement HGPs in clinical practice. The most promising results were achieved in studies that developed a radiomic algorithm.
Caetano Oliveira R.	Semin Cancer Biol 2021 ¹¹⁸	This review focusses on the possibilities to identify the HGPs when a surgical liver resection specimen is not available (pre-surgery, in patients not eligible for surgical resection of their liver metastases, during systemic treatment to detect a change of HGP as a marker of response/resistance, ...).
Rigamonti A.	Cancers 2021 ¹¹⁹	Parameters that predict clinical behaviour of CRC liver metastases are discussed in this review, the HGP being one of these parameters.
Kurebayashi Y.	Hepatol Res 2021 ⁷⁸	The immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and CRC liver metastases is discussed. Although there is a clear relationship between immune cell infiltration and HGP, the authors conclude that the knowledge of the interaction between cancer cells in the liver, immune cells and non-immune stromal cells is still incomplete and can be expanded by single cell RNA-sequencing.

Garcia-Vicién G.	Int J Mol Sci 2021 ¹²⁰	Several aspects of the liver microenvironment, such as the sinusoidal vasculature, the arterial and venous blood supply, and the specific mesenchymal and immune cell component, are addressed in the context of the HGP of CRC liver metastases. The authors conclude that we still do not know what causes one or the other HGP when cancer cells arrive in the liver and form a metastasis.
Haas G	Front Cell Dev Biol. 2021 ¹²¹	Vessel co-option and the HGPs of liver metastases but also of tumours growing in other organs are discussed. The idea of the distinct metabolic status of cancer cells in the replacement HGP being a potential therapeutic target is launched in this review.
Rompianesi G	World J Gastroenterol 2022 ¹²²	Review of studies implementing artificial intelligence (machine learning and deep learning) in the diagnosis and management of patients with CRC liver metastases. The authors conclude that an accurate identification of the HGPs (by medical imaging) could significantly improve individualized treatment approaches.

Table 6.

Hypotheses to explain the biology of the different HGPs of liver metastases	Supporting evidence and/or supporting argument
<p>Site of implantation</p> <p>The site of cancer cell implantation in the liver determines the HGP</p>	<p>In animal models of liver metastasis (where cancer cells were introduced either via an arterial route or a portal route) the arterial route gave rise to a significantly higher proportion of desmoplastic metastases, originating from within portal tracts, than when cancer cells entered the liver via the vena portae, which more often resulted in a replacement-type liver metastases (Paku S & Lapis K, 1993¹²³; Vidal-Vanaclocha F, 2008¹²⁴).</p>
<p>Revertant <i>in situ</i> growth</p> <p>The replacement HGP is a reversion to <i>in situ</i> growth of cancer cells (growth within the boundaries of a basement membrane)</p>	<p>Cancer cells in replacement-type liver metastases take the place of hepatocytes and rest on the Space of Disse. The hybrid ductular structures (cancer cell-cholangiocyte) and growth within bile ducts are other examples of <i>in situ</i> growth of cancer cells in the liver. Revertant <i>in situ</i> growth has been described in lymph node metastases of cancer which adopt a similar growth pattern with cancer cells replacing lymphocytes and co-opting the vasculature (Barsky SH, 1997¹²⁵).</p>
<p>Coagulation and inflammation</p> <p>The presence (desmoplastic) or absence (replacement) of coagulation and inflammation determine the HGPs</p>	<p>Angiogenesis, coagulation, inflammation, and fibrosis are interrelated processes during wound healing and may also be the driving force behind the desmoplastic HGP of liver metastases. When cancer cells can avoid activating any of these processes, liver metastases can adopt the replacement HGP. Only minimal fibrin deposits and hypoxia, one of the factors inducing</p>

	angiogenesis, occur in liver metastases with a replacement HPG (Stessels F, 2004 ³⁸) and replacement pattern liver metastases often show an ‘immune desert’ (Stremitzer S, 2020 ²).
<p>Response to liver injury</p> <p>The HGPs reflect the response patterns of the liver to injury, with the desmoplastic HGP resembling biliary liver fibrosis and the replacement pattern resembling liver regeneration.</p>	<p>There are two responses to liver injury – the fibrotic response and the liver regeneration response (Ding B, 2014⁸²). The desmoplastic rim contains a portal-type of stroma (this manuscript) and proliferating bile ducts (ductular reaction) which resembles the fibrotic response to liver injury (Schuppan D, 2013¹²⁶). In replacement-type liver metastases, the cancer cells are arranged in cell plates and replace the parenchymal hepatocytes, thereby preserving the vascular architecture of the liver parenchyma, which resembles morphologically progenitor cell-driven liver regeneration (Deszo K, 2012¹²⁷).</p>
<p>Transcriptional reprogramming</p> <p>The HGPs are the result of transcriptional reprogramming driven by an HGP-specific epigenetic landscape.</p>	<p>CRC cells have been shown to express liver-specific genes in liver metastases, thereby losing expression of colon-specific genes. This reprogramming is driven by a change in enhancer-regions in the genome (Teng S, 2020⁵²). In the replacement HGP, cancer tissue mimics liver tissue histologically, supporting the hypothesis that cancer cells switch on a liver organogenesis program that may be driven by the sinusoidal endothelial cells as in vascularizing organogenesis (Matsumoto K, 2001⁸⁰; Crivellato E, 2007⁸¹; Ding B, 2014⁸²; Daniel E, 2019⁸³). Desmoplastic liver metastases histologically resemble the primary colorectal tumour and may also have a similar transcriptional profile.</p>
<p>Cancer cell motility</p>	


<p>The ability of cancer cells to move and migrate determines the HGPs because cancer cell motility is necessary for the replacement HGP.</p>	<p>Knocking down of <i>ARPC3</i>, a gene coding for a subunit of an actin nucleating complex necessary for cell motility, or <i>RUNX1</i>, coding for Runt Related Transcription Factor-1 (which is upstream of ARP2/3) changes the HGP from a replacement pattern to a desmoplastic pattern in an animal model of liver metastasis (Frentzas S, 2016⁴¹; Rada M, 2021¹¹¹).</p>
<p>Replacement HGP is the default</p> <p>The replacement HGP is the default growth pattern.</p>	<p>Remnants of co-opted portal triads are present in the centre of liver metastases, independent of the HGP. This suggests that desmoplastic liver metastases originate from replacement-type metastases, given that co-option of portal triads is not observed at the interface with the liver in desmoplastic liver metastases. Cancer cells also replace normal epithelial cells when they spread within a bile duct or form hybrid structures with cholangiocytes of a ductular reaction (this manuscript), supporting the idea the cancer cells have a natural tendency to interact with normal cells. What induces the transition from replacement to desmoplastic growth is still unknown.</p>
<p>Angiotropic extravascular migration and pericyte mimicry</p> <p>The replacement HGP relies on these processes.</p>	<p>Both the growth along sinusoidal blood vessels via angiotropic migration and pericyte mimicry and the histological resemblance of replacement liver metastases to liver parenchyma suggest that programs of embryogenesis are active in this type of metastases (Lugassy C, 2020³³).</p>

Figure 1


A




B




C




D




E




F




G




H




I




J




K






415	362	308	257	203	156	119	86	65	45	32
-----	-----	-----	-----	-----	-----	-----	----	----	----	----


1516	1291	986	714	526	379	271	204	147	103	77
------	------	-----	-----	-----	-----	-----	-----	-----	-----	----



415	362	308	257	203	156	119	86	65	45	32
461	390	290	214	159	112	82	57	43	28	20
305	256	198	139	100	72	55	45	36	26	21
549	466	352	246	177	124	85	69	48	35	26
201	179	146	115	90	71	49	33	20	14	10




1031	882	705	551	421	311	233	167	128	88	66
839	720	551	397	288	208	145	111	75	55	40
19	17	9	8	7	4	3	3	2	1	0
42	34	29	15	13	12	9	9	7	4	3




415	256	172	140	106	82	64	51	40	29	22
-----	-----	-----	-----	-----	----	----	----	----	----	----

1516	668	373	273	207	157	125	102	79	63	48
------	-----	-----	-----	-----	-----	-----	-----	----	----	----




415	256	172	140	106	82	64	51	40	29	22
461	212	111	80	60	42	33	26	18	15	11
305	132	78	53	38	29	27	25	22	17	13
549	227	126	91	71	55	43	33	26	21	16
201	97	58	49	38	31	22	18	13	10	8



1031	538	320	247	187	141	114	92	70	53	42
839	362	211	157	121	93	72	58	46	36	26
19	6	3	2	1	1	1	1	1	1	0
42	18	11	7	4	4	2	2	2	2	2

Figure 3

A



B







Figure 4

A





CK19-CK18

B





CK19-CK18

C



CK20-CK7


D




CK20-CK7

Figure 5

A




Patient




PDX

B




Patient



PDX

Figure 6

A



B






Figure 7

A





Caldesmon-CK7-CD34




CD146-NGFR

B




CK20-CK7

C




CK20-CK7


D




CD146-NGFR



CK18-SMA



E



CK19-CK18

Table 2.

	Desmoplastic	Replacement	Pushing	Sinusoidal	Portal (including intrabiliary)
General architecture	A desmoplastic rim separates metastatic tissue from liver tissue.	Cancer cell are arranged in plates in continuity with the hepatocyte plates.	Metastatic tissue pushes the liver tissue aside (without recognizable desmoplastic rim).	Cancer cells grow in the sinusoidal vessel lumina or in the Disse space, adjacent to the hepatocyte plates.	Metastatic tissue grows within portal tracts and septa and/or within the lumen of biliary branches
Liver architecture mimicry	-	+	-	+	n.a.
Liver stroma preserved	-	+	-	+	+
Contact of cancer cells with liver epithelial cells	Not with hepatocytes Occasional contact with cholangiocytes of ductular reaction	+ (hepatocytes)	-	-	With cholangiocytes if intrabiliary growth
Desmoplastic reaction around the metastasis	+	-	-	-	n.a.
Compression of liver cell plates	+	-/+	+	-	n.a.
Contour	sharp	irregular	sharp	irregular	n.a.
Inflammatory cell infiltrate	++	+/-	+/-	+/-	n.a.
Proliferation of bile ducts (ductular reaction)	+/-	-	-	-	-/+
Glandular differentiation (if adenocarcinoma)	+	-	+	-	+
	Figures 1A-C	Figures 1D-F	Figures 1G & H	Figure 1I	Figures 1J & K

Table 3. Baseline characteristics

		missing (%)	n = 1931 (%)
Cohort	<i>Erasmus MC</i>		903 (47)
	<i>MSKCC</i>		716 (37)
	<i>Radboud UMC</i>		312 (16)
Age at resection CRLM - (<i>median [IQR]</i>)			64.0 [56.0, 71.0]
Gender	<i>Male</i>		1170 (61)
	<i>Female</i>		761 (39)
ASA classification	<i>ASA I-II</i>	39 (2)	1284 (68)
	<i>ASA >II</i>		609 (32)
Primary tumour location	<i>Left-sided</i>	62 (3)	458 (25)
	<i>Right-sided</i>		798 (43)
	<i>Rectal</i>		613 (33)
T-stage	<i>pT 0-2</i>	87 (5)	287 (16)
	<i>pT 3-4</i>		1557 (84)
N-stage	<i>N0</i>	31 (2)	729 (38)
	<i>N+</i>		1172 (62)
Number of CRLM - (<i>median [IQR]</i>)		12 (1)	2.0 [1.0, 3.0]
Diameter of largest CRLM in cm - (<i>median [IQR]</i>)		35 (2)	2.8 [1.9, 4.5]
Disease-free interval in months* - (<i>median [IQR]</i>)		14 (1)	1.0 [0.0, 17.0]
Synchronous (DFI ≤3 months)	<i>Synchronous</i>		1023 (53)
	<i>Metachronous</i>		908 (47)
Preoperative CEA in µg/L - (<i>median [IQR]</i>)		143 (7)	11.0 [4.0, 33.7]
Perioperative systemic chemotherapy	<i>No chemotherapy</i>	41 (2)	773 (41)
	<i>Neoadjuvant only</i>		689 (36)
	<i>Adjuvant only</i>		232 (12)
	<i>Perioperative</i>		196 (10)
Resection margin involved	<i>No</i>	10 (1)	1675 (87)
	<i>Yes</i>		247 (13)
Extrahepatic disease**	<i>No</i>		1731 (90)
	<i>Yes</i>		200 (10)

* *Between resection of primary tumour and detection of CRLM*

** *Defined as any extrahepatic disease with the exception of the primary tumour present at the time of or prior to first CRLM surgery.*

Abbreviations in alphabetical order: ASA: American Society of Anaesthesiologists; CEA: carcinoembryonic antigen; CRLM: colorectal liver metastasis; DFI: disease-free interval; Erasmus MC: Erasmus MC Cancer Institute; IQR: interquartile range; MSKCC: Memorial Sloan Kettering Cancer Center; Radboud UMC: Radboud University Medical Center.

Table 4. Overall and disease-free survival estimates for different HGP cut-offs in 1931 patients treated with curative intent resection for CRLM

Cut-off	n (%)	Overall survival (95%CI)				Disease-free survival (95%CI)			
		5 year - %	10 year - %	Median - months	Adjusted HR*	5 year - %	10 year - %	Median - months	Adjusted HR*
Entire cohort	1931 (100)	50 (47-53)	28 (26-32)	60 (56-65)	-	22 (20-24)	18 (16-21)	13 (12-13)	-
Rotterdam cut-off									
Non-desmoplastic	1516 (79)	45 (42-48)	25 (22-28)	53 (49-58)	<i>reference</i>	18 (16-20)	14 (12-17)	11 (11-12)	<i>reference</i>
Desmoplastic	415 (21)	66 (61-72)	42 (35-50)	88 (77-112)	0.64 (0.52-0.78)	38 (33-43)	33 (28-39)	24 (20-33)	0.61 (0.52-0.71)
Rotterdam cut-off - discrete									
100% non-desmoplastic	201 (10)	48 (41-56)	21 (14-31)	57 (44-69)	<i>reference</i>	20 (15-27)	15 (10-23)	12 (10-15)	<i>reference</i>
67.1-99.9% non-desmoplastic	549 (28)	41 (36-46)	22 (18-28)	48 (44-55)	1.13 (0.89-1.45)	17 (14-21)	14 (11-18)	11 (10-12)	1.10 (0.89-1.35)
33.1-67% non-desmoplastic	305 (16)	46 (40-54)	31 (24-39)	55 (45-66)	0.95 (0.72-1.25)	19 (14-24)	16 (12-22)	11 (10-13)	0.99 (0.79-1.25)
0.1-33% non-desmoplastic	461 (24)	49 (44-55)	25 (20-32)	58 (51-70)	1.05 (0.81-1.36)	18 (14-22)	13 (9-17)	12 (11-13)	1.05 (0.85-1.31)
100% desmoplastic	415 (21)	66 (61-72)	42 (35-50)	88 (77-112)	0.67 (0.51-0.88)	38 (33-43)	33 (28-39)	24 (20-33)	0.64 (0.51-0.80)
Predominant HGP cut-off (>50%)									
Predominant replacement	839 (43)	42 (38-46)	23 (19-27)	49 (45-56)	<i>reference</i>	18 (16-22)	15 (12-18)	11 (10-12)	<i>reference</i>
Predominant pushing	19 (1)	34 (17-66)	NA	24 (17-NA)	1.03 (0.55-1.95)	6 (1-37)	NA	8 (4-19)	1.12 (0.64-1.95)
Mixed	42 (2)	47 (33-69)	25 (11-55)	53 (33-129)	1.04 (0.65-1.68)	15 (7-32)	11 (4-29)	11 (8-23)	1.23 (0.84-1.78)
Predominant desmoplastic	1031 (53)	57 (53-61)	34 (30-39)	72 (67-79)	0.76 (0.65-0.88)	26 (23-29)	22 (19-25)	14 (13-17)	0.82 (0.73-0.93)

* Multivariable regression model (n=1565 included in full-case analyses) corrected for age, gender, ASA class, primary tumour location, T-stage, nodal status, disease-free interval (continuous), number of CRLM (continuous), size of largest CRLM (continuous), preoperative CEA (continuous), extrahepatic disease, resection margin status, and perioperative systemic chemotherapy.

Abbreviations in alphabetical order: ASA: American Society of Anaesthesiologists; CEA: carcinoembryonic antigen; CRLM: colorectal liver metastasis; HGP: histopathological growth pattern; HR: hazard ratio; NA: not available.

Table 5. Standard method for histopathological growth pattern assessment of liver metastases.

- Sampling of resection specimens:
 - Complete sampling (tumour-liver interface and centre) of metastases up to 2 cm.
 - Sampling of a complete central section (tumour-liver interface and centre) of metastases larger than 2 cm.
 - If an alternative sampling method is applied, for example a tumour-type specific approach, this should be reported.
- The growth pattern is a histological parameter assessed by light microscopic imaging of good quality H&E sections of FFPE tissue of resection specimens of liver metastases. Tissue cores from needle biopsy procedures are not suitable for HGP assessment. Resection specimen tissue sections with only a limited part of the tumour-liver interface are considered insufficient to assess the growth pattern of liver metastases. Also, if no viable tumour tissue is present in the metastasis, the growth pattern cannot be assessed. Delayed fixation (autopsy cases), surgical cautery or radiofrequency ablation artifacts may lead to insufficient quality of the tissue sections for scoring the growth patterns.
- The histological growth patterns of liver metastases can be evaluated by a pathologist or by any other investigator trained by a pathologist. The authors of the guidelines may be contacted for training sessions.
- The growth pattern is a characteristic of the tumour–liver interface, more specifically the interface with the adjacent non-tumorous hepatic lobular tissue. The centre of the metastasis does not contribute to the classification of a growth pattern.
- The three common growth patterns are: desmoplastic, pushing and replacement.
- The sinusoidal growth pattern is rare. In addition, metastases can grow in portal tracts and inside biliary ducts.
- When more than one growth pattern is present in a metastasis: estimate the relative fraction of each growth pattern as a percentage of the total length of the interface*.

- In case of multiple metastases/patient: assess the growth pattern(s) in every individual liver metastasis.
- Reporting of the HGPs per patient*:
 - For each metastasis (defined by its largest diameter), report the proportion of the interface with replacement, desmoplastic and pushing HGP (for example: 'metastasis 1: 20% replacement, 80% desmoplastic, 0% pushing).
 - Small areas with a distinct HGP covering less than 5% of the interface should still be reported.
 - The presence of intrabiliary, portal and sinusoidal growth should be reported as a separate remark.
 - 'Escape' should be reported as being absent or present in metastases resected after chemotherapy.
- The categorisation of a patient according to the growth pattern of a liver metastasis or of multiple metastases will depend on the primary tumour type and the aim of the growth pattern assessment.
- Caveats and practical tips:
 - Portal tracts at the tumour–liver interface and growth near the liver capsule (facing the peritoneal surface or soft tissue without intermediate liver parenchyma) should not be considered as part of the tumour-liver interface.
 - Metastatic growth inside portal tracts or biliary ducts should not be regarded as desmoplastic growth.
 - The presence and extent of intrabiliary tumour growth can be underestimated, as the biliary epithelium is often replaced by cancer cells which eventually fill the lumen with accompanying necrosis.
 - Reactive proliferation of bile ducts (ductular reaction) in the desmoplastic rim can simulate a replacement growth pattern. In addition, cancer cells can build common structures with the reactive bile ductuli.
 - In case of severe inflammation and associated tissue changes it may be difficult to identify the growth patterns. The presence of co-opted hepatocytes and tumour cell-hepatocyte contact in the periphery of the metastasis are indicative of the replacement growth pattern. Immunohistochemistry or silver impregnation staining of the sections (e.g.,

Gordon- Sweet's reticulin staining) may be helpful to identify the growth patterns.

- Pushing-type of growth should not be overestimated: only when there is no cancer cell-hepatocyte contact, the pushing HGP can be considered.

*Remark:

Specific scoring and reporting rules may apply to certain tumour types and settings. For example, when the HGPs are assessed to obtain prognostic information in a patient with CRLM, it will be sufficient to look for areas of replacement HGP to distinguish a non-desmoplastic from a desmoplastic status.